axgn_Current_Folio

0001558370-16-007237.txt : 20160803 0001558370-16-007237.hdr.sgml : 20160803 20160803161608 ACCESSION NUMBER: 0001558370-16-007237 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 51 CONFORMED PERIOD OF REPORT: 20160630 FILED AS OF DATE: 20160803 DATE AS OF CHANGE: 20160803 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AxoGen, Inc. CENTRAL INDEX KEY: 0000805928 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 411301878 STATE OF INCORPORATION: MN FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36046 FILM NUMBER: 161804048 BUSINESS ADDRESS: STREET 1: 13859 PROGRESS BLVD. STREET 2: SUITE 100 CITY: ALACHUA STATE: FL ZIP: 32615 BUSINESS PHONE: (386) 462-6817 MAIL ADDRESS: STREET 1: 13859 PROGRESS BLVD. STREET 2: SUITE 100 CITY: ALACHUA STATE: FL ZIP: 32615 FORMER COMPANY: FORMER CONFORMED NAME: LECTEC CORP /MN/ DATE OF NAME CHANGE: 19920703 10-Q 1 axgn-20160630x10q.htm 10-Q axgn_Current_Folio_10Q

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)


☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2016


☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____________ to______________

Commission file number: 001-36046

AxoGen, Inc.

(Exact name of registrant as specified in its charter)


Minnesota		41-1301878
(State or other jurisdiction of		(I.R.S. Employer
incorporation or organization)		Identification No.)


13631 Progress Blvd., Suite 400, Alachua, FL		32615
(Address of principal executive offices)		(Zip Code)

386-462-6800

(Registrant’s telephone number, including area code)

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES ☒ NO ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). YES ☒ NO ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer ☐		Accelerated filer ☐

Non-Accelerated filer ☐ (Do not check if a smaller reporting company)		Smaller reporting company ☒

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES ☐ NO ☒

As of August 3, 2016, the registrant had 30,132,224 shares of common stock outstanding.

Table of Contents


Part I - Financial Information
Item 1.	Financial Statements	2

Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	15

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	21

Item 4.	Controls and Procedures	21


Part II - Other Information

Item 1.	Legal Proceedings	22

Item 1A.	Risk Factors	22

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	22

Item 3.	Defaults Upon Senior Securities	22

Item 4.	Mine Safety Disclosures	22

Item 5.	Other Information	22

Item 6.	Exhibits	23

	Signature Page	24

Forward-Looking Statements

From time to time, in reports filed with the U.S. Securities and Exchange Commission (the “SEC”) (including this Form 10-Q), in press releases, and in other communications to shareholders or the investment community, AxoGen, Inc. (the “Company”, “AxoGen”, “we” or “our”) may provide forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995, concerning possible or anticipated future results of operations or business developments. These statements are based on management’s current expectations or predictions of future conditions, events or results based on various assumptions and management’s estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as "expects", "anticipates", "intends", "plans", "believes", "seeks", "estimates", "projects", "forecasts", "continue", "may", "should", "will" variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements may include, without limitation, statements regarding our growth, our 2016 guidance, product development, product potential, financial performance, sales growth, product adoption, market awareness of our products, data validation, our visibility at and sponsorship of conferences and educational events. The forward-looking statements are subject to risks and uncertainties, which may cause results to differ materially from those set forth in the statements. Forward-looking statements in this Form 10-Q should be evaluated together with the many uncertainties that affect the Company’s business and its market, particularly those discussed in the risk factors and cautionary statements in the Company’s filings with the SEC, including as described in “Risk Factors” included in Item 1A of this Form 10-Q. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made, and the Company assumes no responsibility to update any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law.

Table of Contents

PART 1 — FINANCIAL INFORMATION

ITEM 1 —FINANCIAL STATEMENTS

AxoGen, Inc.

Condensed Consolidated Balance Sheets


	June 30,		December 31,
	2016 (unaudited)		2015

Assets
Current assets:
Cash and cash equivalents	$	18,273,203	$	25,909,500
Accounts receivable, net of allowance for doubtful accounts of approximately $241,000 and $192,000 respectively		6,072,121		4,782,989
Inventory		4,786,322		3,933,960
Prepaid expenses and other		615,511		424,925
Total current assets		29,747,157		35,051,374
Property and equipment, net		1,260,190		970,870
Intangible assets		743,390		678,082
	$	31,750,737	$	36,700,326
Liabilities and Shareholders’ Equity
Current liabilities:
Accounts payable and accrued expenses	$	3,893,834	$	3,695,127
Current deferred revenue		28,593		14,118
Total current liabilities		3,922,427		3,709,245

Note Payable - Revenue Interest Purchase Agreement		24,952,201		24,701,693
Long Term Deferred Revenue		83,006		93,797
Total liabilities		28,957,634		28,504,735
Shareholders’ equity:
Common stock, $0.01 par value per share; 50,000,000 shares authorized; 30,128,099 and 29,984,591 shares issued and outstanding		301,281		299,846

Additional paid-in capital		112,443,288		111,368,424
Accumulated deficit		(109,951,466)		(103,472,679)
Total shareholders’ equity		2,793,103		8,195,591
	$	31,750,737	$	36,700,326

See notes to condensed consolidated financial statements.

Table of Contents

AxoGen, Inc.

Condensed Consolidated Statements of Operations

(unaudited)


	Three Months Ended				Six Months Ended
	June 30,		June 30,		June 30,		June 30,
	2016		2015		2016		2015
Revenues	$	10,381,883	$	6,417,253	$	18,493,642	$	11,368,569
Cost of goods sold		1,534,412		1,039,841		2,940,003		2,022,722
Gross profit		8,847,471		5,377,412		15,553,639		9,345,847
Costs and expenses:
Sales and marketing		6,780,363		4,812,262		12,986,238		8,744,783
Research and development		936,823		736,399		1,915,163		1,407,435
General and administrative		2,736,255		1,982,020		4,881,012		3,890,602
Total costs and expenses		10,453,441		7,530,681		19,782,413		14,042,820
Loss from operations		(1,605,970)		(2,153,269)		(4,228,774)		(4,696,973)
Other income (expense):
Interest expense		(1,163,413)		(1,023,774)		(2,166,440)		(2,018,522)
Interest expense — deferred financing costs		(32,696)		(31,210)		(63,506)		(64,956)
Other income (expense)		(617)		17,380		(20,067)		14,378
Total other income (expense)		(1,196,726)		(1,037,604)		(2,250,013)		(2,069,100)
Net Loss	$	(2,802,696)	$	(3,190,873)	$	(6,478,787)	$	(6,766,073)
Weighted Average Common Shares outstanding — basic and diluted		30,079,960		24,928,435		30,037,013		23,729,558
Loss Per Common share — basic and diluted	$	(0.09)	$	(0.13)	$	(0.22)	$	(0.29)

See notes to condensed consolidated financial statements.

Table of Contents

AxoGen, Inc.

Condensed Consolidated Statements of Cash Flows

(unaudited)


	Six Months Ended June 30,
	2016		2015
Cash flows from operating activities:
Net loss	$	(6,478,787)	$	(6,766,073)
Adjustments to reconcile net loss to net cash used for operating activities:
Depreciation		167,590		87,610
Amortization of intangible assets		32,033		22,710
Amortization of deferred financing costs		63,506		64,957
Provision for bad debt		48,600		—
Stock-based compensation		752,789		696,625
Interest added to note payable		187,002		340,870
Change in assets and liabilities:
Accounts receivable		(1,337,732)		(965,715)
Inventory		(852,362)		(326,337)
Prepaid expenses and other		(190,586)		(131,739)
Accounts payable and accrued expenses		198,707		976,928
Deferred revenue		3,684		(10,791)

Net cash used for operating activities		(7,405,556)		(6,010,955)

Cash flows from investing activities:
Purchase of property and equipment		(456,910)		(132,492)
Acquisition of intangible assets		(97,341)		(54,075)

Net cash used for investing activities		(554,251)		(186,567)

Cash flows from financing activities:
Proceeds from issuance of common stock		—		13,770,734
Debt issuance costs		—		(180,142)
Proceeds from exercise of stock options		323,510		14,071

Net cash provided by financing activities		323,510		13,604,663

Net increase (decrease) in cash and cash equivalents		(7,636,297)		7,407,141
Cash and cash equivalents, beginning of year		25,909,500		8,215,791

Cash and cash equivalents, end of period	$	18,273,203	$	15,622,932

Supplemental disclosures of cash flow activity:
Cash paid for interest	$	1,964,256	$	1,649,881

See notes to condensed consolidated financial statements.

Table of Contents

AxoGen, Inc.

Notes to Condensed Consolidated Financial Statements

(unaudited)

Unless the context otherwise requires, all references in these Notes to “AxoGen,” “the Company,” “we,” “us” and “our” refer to AxoGen, Inc. and its wholly owned subsidiary AxoGen Corporation (“AC”).

1. Basis of Presentation

The accompanying condensed consolidated financial statements include the accounts of AxoGen, Inc. (the “Company” or “AxoGen”) and its wholly owned subsidiary AxoGen Corporation (“AC”) as of June 30, 2016 and December 31, 2015 and for the three and six month periods ended June 30, 2016 and 2015. The Company’s condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and should be read in conjunction with the audited financial statements of the Company for the year ended December 31, 2015, which are included in the Company’s Annual Report on Form 10-K as of and for the year ended December 31, 2015. The interim condensed consolidated financial statements are unaudited and in the opinion of management, reflect all adjustments necessary for a fair presentation of results for the periods presented. Results for interim periods are not necessarily indicative of results for the full year. All significant intercompany accounts and transactions have been eliminated in consolidation.

2. Organization and Business

Business Summary

We are a global leader in innovative surgical solutions for peripheral nerve injuries. Our portfolio of products includes Avance® Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard® Nerve Connector, a porcine submucosa extracellular matrix ("ECM") coaptation aid for tensionless repair of severed nerves, and AxoGuard® Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments. Along with these core surgical products, AxoGen also offers AxoTouchTM Two-Point Discriminator and AcroValTM Neurosensory & Motor Testing System. These evaluation and measurement tools assist healthcare professionals in detecting changes in sensation, assessing return of sensory, grip and pinch function, evaluating effective treatment interventions, and providing feedback to patients on nerve function. The AxoGen portfolio of products is available in the United States, Canada, the United Kingdom and several European and international countries.

Avance® Nerve Graft is processed in the United States by AxoGen. AxoGuard® Nerve Connector and AxoGuard® Nerve Protector are manufactured in the United States by Cook Biotech Incorporated and are distributed worldwide exclusively by AxoGen. The AcroVal™ Neurosensory and Motor Testing System and AxoTouch™ Two Point Discriminator are contract manufactured by Viron Technologies, LLC. (formerly Cybernetics Research Laboratories) (“Viron”), Tucson, Arizona. Viron supplies the AcroVal™ and AxoTouch™ unpackaged and they are packaged at AxoGen’s distribution facility in Burleson, Texas. AxoGen maintains its corporate offices in Alachua, Florida and is the parent company of its wholly owned operating subsidiary, AC.

3. Summary of Significant Accounting Policies

Revenue Recognition

Table of Contents

customer. Fees charged to customers for shipping are recognized as revenues when products are shipped to the customer, distributor or end user. In the case of revenues from consigned sales, revenue is determined when the product is utilized in a surgical procedure. Revenues from research grants are recognized in the period the associated costs are incurred.

Cash and Cash Equivalents and Concentration

For purposes of the statement of cash flows, the Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents. Cash and cash equivalents are maintained at financial institutions and, at times, balances may exceed federally insured limits. The Company has never experienced any losses related to these balances and does not believe it is exposed to any significant credit risk on cash and cash equivalents.

Accounts Receivable and Concentration of Credit Risk

Accounts receivable are carried at the original invoice amount less an estimate made for doubtful accounts based on a review of all outstanding amounts on a monthly basis. Management determines the allowance for doubtful accounts by regularly evaluating individual customer receivables and considering a customer’s financial condition, credit history and current economic conditions. Accounts receivable are written off when deemed uncollectible. Recoveries of accounts receivable previously written off are recorded when received.

We regularly review all accounts that exceed 60 days from the invoice date and based on an assessment of current credit worthiness, estimate the portion, if any, of the balance that will not be collected. The analysis excludes certain government related receivables due to our past successful experience in collectability. Specific accounts that are deemed uncollectible are reserved at 100% of their outstanding balance. The remaining balances outstanding over 60 days have a percentage applied by aging category (5% for balances 61-90 days and 20% for balances over 90 days aged), based on a historical valuation that allows us to calculate the total reserve required. The reserve balance was determined by applying a percentage to the cumulative balance between 60 and 90 days and a higher percentage to the balance over 90 days. In the event that we exhaust all collection efforts and deem an account uncollectible, we would subsequently write off the account. The write off process involves approval by senior management based on the write off amount. The allowance for doubtful accounts reserve balance was approximately $241,000 and $192,000 at June 30, 2016 and December 31, 2015, respectively.

Concentrations of credit risk with respect to accounts receivable are limited because a large number of geographically diverse customers make up the Company’s customer base, thus spreading the trade credit risk. The Company also controls credit risk through credit approvals, credit limits and monitoring procedures.

Inventories

Inventories are comprised of implantable tissue, nerve grafts, Avance® Nerve Graft, AxoGuard® Nerve Connector, AxoGuard® Nerve Protector, and supplies that are valued at the lower of cost (first-in, first-out) or market and consist of the following:


	June 30,		December 31,
	2016		2015

Finished goods	$	3,243,883	$	2,732,823
Work in process		187,177		237,108
Raw materials		1,355,262		964,029
	$	4,786,322	$	3,933,960

Inventories were net of reserve of approximately $820,000 and $711,000 at June 30, 2016 and December 31, 2015, respectively.

Table of Contents

Income Taxes

The Company has not recorded current income tax expense due to the generation of net operating losses. Deferred income taxes are accounted for using the balance sheet approach which requires recognition of deferred tax assets and liabilities for the expected future consequences of temporary differences between the financial reporting basis and the tax basis of assets and liabilities. A valuation allowance is provided when it is more likely than not that a deferred tax asset will not be realized. A full valuation allowance has been established on the deferred tax asset as it is more likely than not that a future tax benefit will not be realized. In addition, future utilization of the available net operating loss carryforward may be limited under Internal Revenue Code Section 382 as a result of changes in ownership.

The Company identifies and evaluates uncertain tax positions, if any, and recognizes the impact of uncertain tax positions for which there is a less than more-likely-than-not probability of the position being upheld when reviewed by the relevant taxing authority. Such positions are deemed to be unrecognized tax benefits and a corresponding liability is established on the balance sheet. The Company has not recognized a liability for uncertain tax positions. If there were an unrecognized tax benefit, the Company would recognize interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses. The Company’s remaining open tax years subject to examination by the Internal Revenue Service include the years ended December 31, 2012 through 2015; there currently are no examinations in process.

Fair Value of Financial Instruments

The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include cash, accounts receivable, accounts payable and accrued expenses. The fair value of the Company’s long-term debt approximates its carrying value based upon current rates available to the Company.

Share-Based Compensation

Stock-based compensation cost related to stock options granted under the AC 2002 Stock Option Plan and AxoGen 2010 Stock Incentive Plan (see Note 8) is measured at grant date, based on the fair value of the award, and is recognized as an expense over the employee’s requisite service period. The Company estimates the fair value of each option award issued under the Plan on the date of grant using a Black-Scholes-Merton option-pricing model that uses the assumptions noted in the table below. The Company estimates the volatility of its common stock at the date of grant based on the volatility of comparable peer companies which are publicly traded, for the periods prior to there being a market for the Company’s common stock, and based on the Company’s common stock for periods subsequent to having an established market for the stock. The Company determines the expected life based on historical experience with similar awards, giving consideration to the contractual terms, vesting schedules and post-vesting forfeitures. The Company uses the risk-free interest rate on the implied yield currently available on U.S. Treasury issues with an equivalent remaining term approximately equal to the expected life of the award. The Company has never paid any cash dividends on its common stock and does not anticipate paying any cash dividends in the foreseeable future. The Company used the following weighted-average assumptions for options granted during the six months ended June 30:


Six months ended June 30,	2016		2015

Expected term (in years)	4		4
Expected volatility	61.85	%	76.24	%
Risk free rate	1.23	%	1.21	%
Expected dividends	—	%	—	%

The Company estimates forfeitures when recognizing compensation expense and this estimate of forfeitures is adjusted over the requisite service period based on the extent to which actual forfeitures differ, or are expected to differ, from such estimates. Changes in estimated forfeitures are recognized through a cumulative catch-up adjustment, which is recognized in the period of change, and also impact the amount of unamortized compensation expense to be recognized in future periods. The Company did not apply a forfeiture allocation to its unvested options outstanding during the six months ended June 30, 2016 and 2015 as they were deemed insignificant.

Table of Contents

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Recent Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board, or FASB issued a new standard on revenue recognition which outlines a single comprehensive model to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The core principle of the revenue model is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The standard is designed to create greater comparability for financial statement users across industries and jurisdictions and also requires enhanced disclosures. The guidance was scheduled to become effective for fiscal years, and interim periods within those years, beginning after December 15, 2016; however, on July 9, 2015, the FASB decided to delay the effective date of the new revenue standard by one year. The proposed deferral may permit early adoption, but would not allow adoption any earlier than the original effective date of the standard. We are currently evaluating the impact this standard will have on our consolidated financial statements.

In June 2014, the FASB issued updated guidance related to stock compensation. The amendment requires that a performance target that affects vesting and that could be achieved after the requisite period, be treated as a performance condition. The updated guidance became effective for annual reporting periods and interim periods within those annual periods beginning after December 15, 2015. The Company has one such stock option grant that is based on quarterly performance conditions and the vesting and compensation expense is measured subsequent to the end of each quarter over a two year period. If the performance condition is met the vesting and compensation expense is recognized on the measurement date.

In April 2015, the FASB issued Accounting Standard Update (“ASU”) No. 2015-03, "Simplifying the Presentation of Debt Issuance Costs" ("ASU 2015-03") which changes the presentation of debt issuance costs in financial statements to present such costs as a direct deduction from the related debt liability rather than as an asset. ASU 2015-03 became effective for public companies during interim and annual reporting periods beginning after December 15, 2015. Early adoption is permitted. The Company adopted this standard in the first quarter of 2016 on a retrospective basis. (See note 7)

In November 2015, the FASB issued an ASU to simplify the presentation of deferred income taxes. The amendments in this ASU require that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. The amendments in these ASU may be applied either prospectively to all deferred tax liabilities and assets or retrospectively to all periods presented and are effective for interim and annual reporting periods beginning after December 15, 2016. Earlier application is permitted for all entities as of the beginning of an interim or annual reporting period. We are currently evaluating the impact this standard will have on our consolidated financial statements.

In January 2016, the FASB, issued ASU 2016-01 “Recognition and Measurement of Financial Assets and Financial Liabilities,” which requires that most equity instruments be measured at fair value, with subsequent changes in fair value recognized in net income. The pronouncement also impacts the financial liabilities under the fair value option and the presentation and disclosure requirements for financial instruments. The ASU does not apply to equity method investments or investments in consolidated subsidiaries. The new standard will be effective for us for the year ending December 31, 2018, with early adoption permitted and amendments to be applied as a cumulative-effect adjustment to the balance sheet in the year of adoption. We are currently evaluating the impact this standard will have on our consolidated financial statements.

Table of Contents

In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842)”. This update will increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. This update is effective for annual and interim reporting periods beginning after December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted. We are currently evaluating the impact this standard will have on our consolidated financial statements.

In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718), Improvements to Employee Share-Based Payment Accounting. The ASU was issued as part of the FASB Simplification Initiative and involves several aspects of accounting for shared-based payment transactions, including the income tax consequences, options to elect forfeiture accounting policy either by the number of awards that are expected to vest (current GAAP) or account for forfeitures when they occur, and classification on the statement of cash flows. The guidance is effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Early adoption is permitted for any entity in any interim or annual period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. An entity that elects early adoption must adopt all of the amendments in the same period. We are currently evaluating the impact this standard will have on our consolidated financial statements.

The Company’s management has reviewed and considered all other recent accounting pronouncements and we believe there are none that could potentially have a material impact on the Company’s consolidated financial condition, results of operations, or disclosures.

4. Property and Equipment

Property and equipment consist of the following:


	June 30,		December 31,
	2016		2015

Furniture and equipment	$	1,119,698	$	1,186,815
Leasehold improvements		490,214		346,642
Processing equipment		1,756,214		1,375,759
Less: accumulated depreciation and amortization		(2,105,936)		(1,938,346)

Property and equipment	$	1,260,190	$	970,870

5. Intangible Assets

The Company’s intangible assets consist of the following:


	June 30,		December 31,
	2016		2015

License agreements	$	907,545	$	897,594
Patents		267,387		179,997
Less: accumulated amortization		(431,542)		(399,509)
Intangible assets, net	$	743,390	$	678,082

License agreements are being amortized over periods ranging from 17-20 years. Patent costs were being amortized over three years. As of June 30, 2016, the patents were fully amortized, and the remaining patents of $267,387 were pending patent costs and were not amortizable. Amortization expense was approximately $16,000 and $11,000 for the three months ended June 30, 2016 and 2015, respectively, and approximately $32,000 and $23,000 for the six months ended June 30, 2016 and 2015, respectively. As of June 30, 2016, future amortization of license agreements for the remainder of this year and the next seven years is expected to be $32,000 for 2016, $64,000 for 2017 through 2022 and $60,000 for 2023.

Table of Contents

License Agreements

The Company has entered into multiple license agreements (the “License Agreements”) with the University of Florida Research Foundation and the University of Texas at Austin. Under the terms of the License Agreements, the Company acquired exclusive worldwide licenses for underlying technology used in repairing and regenerating nerves. The licensed technologies include the rights to issued patents and patents pending in the United States and international markets. The effective term of the License Agreements extends through the term of the related patents and the agreements may be terminated by the Company with 60 days prior written notice. Additionally, in the event of default, licensors may terminate an agreement if the Company fails to cure a breach after written notice. The License Agreements contain the key terms listed below:

AxoGen pays royalty fees ranging from 1% to 3% under the License Agreements based on net sales of licensed products. One of the agreements also contains a minimum royalty of $12,500 per quarter, which may include a credit in future quarters in the same calendar year for the amount the minimum royalty exceeds the royalty fees. Also, when AxoGen pays royalties to more than one licensor for sales of the same product, a royalty stack cap applies, capping total royalties at 3.75%;

If AxoGen sublicenses technologies covered by the License Agreements to third parties, AxoGen would pay a percentage of sublicense fees received from the third party to the licensor. Currently, AxoGen does not sublicense any technologies covered by License Agreements. The Company is not considered a sub-licensee under the License Agreements and does not owe any sublicensee fees for its own use of the technologies;

AxoGen reimburses the licensors for certain legal expenses incurred for patent prosecution and defense of the technologies covered by the License Agreements; and

Currently, under the University of Texas at Austin’s agreement, AxoGen would owe a $15,000 milestone fee upon receiving a Phase II Small Business Innovation Research or Phase II Small Business Technology Transfer grant involving the licensed technology. The Company has not received either grant and does not owe such a milestone fee. A Milestone fee to the University of Florida Research Foundation of $2,000 is due if AxoGen receives FDA approval of its Avance® Nerve Graft, $25,000 upon first commercial use of certain licensed technology to provide services to manufacture products for third parties and $10,000 upon first use to manufacture products that utilize certain technology that is not currently incorporated into AxoGen products.

Royalty fees were approximately $217,000 and $121,000 during the three months ended June 30, 2016 and 2015, respectively, and approximately $370,000 and $217,000 for the six months ended June 30, 2016 and 2015, respectively, and are included in sales and marketing expense on the accompanying condensed consolidated statements of operations.

6. Accounts Payable and Accrued Expenses

Accounts payable and accrued expenses consist of the following:


	June 30,		December 31,
	2016		2015
Accounts payable	$	1,863,349	$	2,090,874
Miscellaneous accruals		358,221		15,183
Accrued compensation		1,672,264		1,589,070
Accounts Payable and Accrued Expenses	$	3,893,834	$	3,695,127

Table of Contents

7. Term Loan Agreement

Term Loan Agreement consists of the following:


	June 30,		December 31,
	2016		2015
Term Loan and Revenue Interest Agreement with Three Peaks Capital S.a.r.l. for a total term loan amount of $25,000,000 which has a six year term and requires interest only payments and a final principal payment due at the end of the term. Interest is payable quarterly at 9.00% per annum plus the greater of LIBOR or 1.0% which as of June 30, 2016 and December 31, 2015 resulted in a 10% rate. The Revenue Interest Agreement is for a period of ten years. Royalty payments are based on a royalty rate of 3.75% of revenues up to a maximum of $30 million in revenues in any 12 month period.	$	24,952,201	$	24,701,693
Long-term portion	$	24,952,201	$	24,701,693

In the first quarter of 2016, the Company adopted ASU 2015-03, “Simplifying the Presentation of Debt Issuance Costs.” ASU 2015-03 requires debt issuance costs related to recognized debt liabilities to be presented in the balance sheet as a direct deduction from the debt liability rather than an asset. Accordingly, as of June 30, 2016, approximately $782,000 of deferred debt issuance costs were presented as a direct deduction within Long-Term Debt on the Company’s Condensed Consolidated Balance Sheets. Furthermore, the Company reclassified approximately $846,000 of deferred debt issuance costs from Other Assets – Deferred Financing Costs to Long-Term Debt as of December 31, 2015.

Term Loan Agreement and Revenue Interest Agreement

On November 12, 2014 (the “Signing Date”), AxoGen, as borrower, and AC, as guarantor, entered into a term loan agreement (the “Term Loan Agreement”) with the lenders party thereto and Three Peaks Capital S.a.r.l. (“Three Peaks”), an indirect wholly-owned subsidiary of Oberland Capital Healthcare Master Fund LP (“Oberland”), as administrative and collateral agent for the lenders thereto. Under the Term Loan Agreement, Three Peaks has agreed to lend to AxoGen a term loan of $25 million (the “Initial Term Loan”) which has a six year term and requires interest only payments and a final principal payment due at the end of the term. Interest is payable quarterly at 9.00% per annum plus the greater of LIBOR or 1.0% which as of November 13, 2014 (“the Initial Closing Date”) resulted in a 10% interest rate. Under certain conditions, as provided in the Term Loan Agreement, as amended by Amendment 1 to the Term Loan Agreement, dated June 29, 2016, by and among the parties to the Loan Agreement (the “Term Loan Agreement Amendment”), AxoGen has the option to draw an additional $7 million (the “Subsequent Borrowing” and, together with the Initial Term Loan, the “Term Loan”) during the period of July 1, 2016 through September 30, 2016 (the closing date of each such Subsequent Borrowing, a “Subsequent Closing Date” and, together with the Initial Closing Date, the “Closing Dates”) under similar terms and conditions. AxoGen has to comply with certain covenants including limiting new indebtedness, restricting the payment of dividends and maintaining certain levels of revenue. Three Peaks has a first perfected security interest in the assets of AxoGen.

In addition, AxoGen entered into a 10 year Revenue Interest Agreement (the “Revenue Interest Agreement”) with Three Peaks. Royalty payments are based on a royalty rate of 3.75% of AxoGen’s revenues up to a maximum of $30 million in revenues in any 12 month period. In the event the Subsequent Borrowing is drawn, the royalty rate increases proportionally up to a maximum of 4.80% AxoGen has to comply with certain covenants including those covenants under the Term Loan.

Table of Contents

Closing Date, 150% of the outstanding principal amount of the Term Loan or any portion being prepaid; or (iv) after the third anniversary of the applicable Closing Date, an amount generating an internal rate of return of 16.25% of the outstanding principal amount of the Term Loan or any portion being prepaid. In all cases, the amount due is reduced by the sum of interest and principal previously paid and all amounts received under the Revenue Interest Agreement. In each such case AxoGen will also owe an additional 3% of the originally advanced Term Loan amount. Upon payment to Three Peaks, AxoGen would have no further obligations to Three Peaks under the Term Loan or the Revenue Interest Agreement.

In connection with the Term Loan Agreement, on the Signing Date, the Company and AC, its wholly owned subsidiary, entered into a Security Agreement (the “Security Agreement”) with Three Peaks, pursuant to which each of the Company and AC grants to Three Peaks a security interest in certain collateral as specified in the Security Agreement to guarantee the payment in full when due of the secured obligations. In the event of default per the terms of the Term Loan Agreement, Three Peaks would have the ability to foreclose on the pledged collateral and the Company and AC would not be able to continue its current business if such foreclosure occurred.

Also in connection with the above transaction, the Company sold 1,375,969 shares of its common stock to Three Peaks for a total of $3.55 million (“Three Peaks Equity Sale”) at a price of $2.58 per share. Pursuant to the equity purchase provisions in the Three Peaks Term Loan Agreement, in the event that, prior to November 12, 2016, we sell our securities at a lower price per share than the $2.58 per share paid by Three Peaks, or where the terms of such subsequent sale are otherwise more favorable, then in such case we have agreed to match the more favorable terms of such subsequent sale with respect to the shares purchased by Three Peaks. A subsequent sale does not include the issuance of securities or options to our employees, officers, directors or consultants pursuant to our approved employee option pool or any other employee stock purchase or option plan existing as of November 12, 2014.

The Company records interest using its best estimate of the effective interest rate. This estimate takes into account both the rate on the Term Loan Agreement and the rate associated with the 10 year Revenue Interest Agreement with Three Peaks. The effective interest rate is based on actual payments to date, projected future revenues and the projected royalty payments and the quarterly interest payments due on the Term Loan Agreement. From time to time, AxoGen will reevaluate the expected cash flows and may adjust the effective interest rate. Determining the effective interest rate requires judgment and is based on significant assumptions related to estimates of the amounts and timing of future revenue streams. Determination of these assumptions is highly subjective and different assumptions could lead to materially different outcomes.

8. Stock Options

The Company granted stock options to purchase 505,750 shares of its common stock pursuant to the AxoGen Plan for the six months ended June 30, 2016. Stock-based compensation expense was $569,834 and $328,376 for the three months ended June 30, 2016 and 2015, respectively and $752,789 and $696,625 for the six months ended June 30, 2016 and 2015, respectively. In the period August 2015 through March 2016, we issued 739,000 stock options to certain officers, directors and employees under the AxoGen 2010 stock option plan. The options were subject to shareholder approval to increase the number of shares authorized under the plan. On May 26, 2016, the shareholder approval was obtained and as a result we recognized stock-based compensation of $272,240 related to these options for the three months ended June 30, 2016. Total future stock compensation expense related to nonvested awards is expected to be approximately $2,959,000 at June 30, 2016.

9. Public Offering of Common Stock

On February 5, 2015, AxoGen entered into an underwriting agreement with Wedbush Securities Inc. (the “Underwriter”) in connection with the offering, issuance and sale (the “February 2015 Offering”) of 4,728,000 shares of the Company’s common stock, at a price to the public of $2.75 per share. The Company also granted to the Underwriter a 30-day option to purchase up to an aggregate of 709,200 additional shares of the Company’s common stock to cover over-allotments, if any.

Table of Contents

As of February 13, 2015, the February 2015 Offering was completed with the sale of 5,437,200 shares of the Company’s common stock, which included the full exercise of the over-allotment option, at $2.75 per share, resulting in gross proceeds to AxoGen from the February 2015 Offering of approximately $15.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by AxoGen estimated at approximately $1.4 million. The shares of Company common stock were listed on the NASDAQ Capital Market. The February 2015 Offering was made pursuant to the Company’s effective shelf registration statement on Form S-3 (Registration No. 333-195588) previously filed with the SEC on April 30, 2014, and pursuant to the prospectus supplement and the accompanying prospectus describing the terms of the February 2015 Offering, dated February 5, 2015.

On August 26, 2015, the Company entered into the Purchase Agreement with Essex Woodlands Fund IX, L.P. for the purchase of 4,861,111 shares of the Company’s common stock at a public offering price of $3.60 per share, raising approximately $17.5 million in gross proceeds (the “August 2015 Offering”). The expenses directly related to the August 2015 Offering were approximately $300,000 and were all paid as of December 31, 2015 by the Company. Such expenses include the Company’s legal and accounting fees, printing expenses, transfer agent fees and miscellaneous fees and costs related to the August 2015 Offering. Proceeds from the August 2015 Offering will be used for sales and marketing and general working capital purposes. The Company has provided certain demand and “piggy-back” registration rights in connection with this sale of its common stock. The August 2015 Offering was made pursuant to the Company’s effective shelf registration statement on Form S-3 (Registration No. 333-195588) previously filed with the SEC on April 30, 2014 and pursuant to the prospectus supplement and the accompanying prospectus describing the terms of the August 2015 Offering, dated August 26, 2015.

The August 2015 Offering was made pursuant to the Company’s effective shelf registration statement on Form S-3 (Registration No. 333-195588) previously filed with the SEC on April 30, 2014, and pursuant to the prospectus supplement and the accompanying prospectus describing the terms of the Offering, dated August 26, 2015.

10. Commitments and Contingencies

Commercial Lease

On March 16, 2016, AC entered into the Fourth Amendment to Lease (“Fourth Amendment”) with SNH Medical Office Properties Trust, a Maryland real estate investment trust (“SNH”). SNH is the landlord of AC’s currently leased 11,761 square foot corporate headquarters facility in Alachua, Florida (the “Current Premises”) pursuant to that certain lease dated as of February 6, 2007, as amended (the “Lease”).

The Fourth Amendment expands the Current Premises by 7,050 square feet (the “Expansion Premises”). The Fourth Amendment also provides that the Expiration Date (as defined in the Fourth Amendment) of the Lease will be extended to approximately five years from the Occupancy Date (as defined in the Fourth Amendment) of the Expansion Premises, which Occupancy Date is occurred in June 2016. The original expiration date of the Current Premises remains unchanged; provided, however, that AC shall have the right to extend the Current Premises Term (as defined in the Fourth Amendment) for three additional periods (the “Current Premises Extended Term”), the first such Current Premises Extended Term to commence on November 1, 2018 and end on October 31, 2019, the second such Current Premises Extended Term to commence on November 1, 2019 and end on October 31, 2020, and the third such Current Premises Extended Term to commence on November 1, 2020 and end on the Expiration Date. AC also has the right to extend the term of the then current Leased Premises (as defined in the Fourth Amendment) for an additional period of five years commencing on the day immediately after the Expiration Date. AC’s additional annual cost of the Expansion Premises will be approximately $123,000, $127,000, $131,000, $135,000 and $139,000 for years one through five, respectively, of the Lease, with year one commencing on the Occupancy Date.

Processing Agreement

Until February 2016, the Company was party to that certain Amended and Restated Nerve Tissue Processing Agreement (the “LifeNet Agreement”) with LifeNet Health (“LifeNet”), whereby the Company processed and packaged Avance® Nerve Graft using its employees and equipment located at LifeNet in Virginia Beach, Virginia (the “Virginia Beach Facility”). As a result of business requirements of LifeNet and their need for additional space, on April 16, 2015 LifeNet notified the Company that it would need to transition out of the Virginia Beach Facility and the LifeNet Agreement was terminated effective February 27, 2016.

Table of Contents

As a result of the termination of the LifeNet Agreement, on August 6, 2015 the Company entered into a License and Services Agreement (the “CTS Agreement”) with Community Blood Center (d/b/a Community Tissue Services) (“CTS”) whose headquarters are located in Dayton, Ohio. The CTS facility and CTS Agreement provides the Company a cost effective, quality controlled and licensed facility to process and package its Avance® Nerve Graft using the Company’s employees and processing equipment. The processing that was performed at the Virginia Beach Facility has been transferred in its entirety to the CTS facility.

The CTS Agreement is for a five-year term, subject to earlier termination by either party for cause, or after the two-year anniversary of the CTS Agreement without cause, upon 18 months notice. Under the CTS Agreement, the Company pays CTS a facility fee for clean room/processing, storage and office space and CTS provides services in support of the Company’s processing such as routine sterilization of daily supplies, providing disposable supplies, microbial services and office support. The service fee is based on a per donor batch rate. However, AxoGen could reproduce a manufacturing space that would meet its needs if it no longer continued its relationship with CTS. AxoGen’s processing methods and process controls have been developed and validated to ensure product uniformity and quality. Pursuant to the CTS Agreement, AxoGen pays license fees on a monthly basis to CTS which total an annual amount of approximately $416,000.

11. Retirement Plan

AxoGen 401(k) Plan

The Company adopted the AxoGen 401(k) plan (the “401(k) Plan”) in December 2015 with contributions starting in January 2016. All full-time employees who have attained the age of 18 are eligible to participate in the 401(k) Plan. Eligibility is immediate upon employment and enrollment is available any time during employment. Participating employees may make annual pretax contributions to their accounts up to a maximum amount as limited by law. The 401(k) Plan requires the Company to make matching contributions of 100% on the first 3% of the employee’s annual salary and 50% of the next 2% of the employee’s annual salary as long as the employee participates in the 401(k) Plan and contributes at least 5% of the annual salary. Both employee contributions and Company contributions vest immediately. Employer contributions to this plan for the three and six months ending June 30, 2016, were $92,145 and $171,401, respectively.

Table of Contents

ITEM 2 – MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Unless the context otherwise requires, all references in this report to “AxoGen,” “the Company,” “we,” “us” and “our” refer to AxoGen, Inc. and its wholly owned subsidiary AxoGen Corporation (“AC”).

OVERVIEW

Revenue from the distribution of these products is the main contributor to AxoGen’s total reported sales and has been the key component of its growth to date. AxoGen’s revenues increased in the first six months of 2016 compared to 2015 primarily as a result of increased product usage by existing accounts and a price increase effective March 1, 2016. This increase is consistent with AxoGen’s sales strategy of focusing largely on growing product usage in its existing accounts.

AxoGen has continued to broaden its sales and marketing activity. This activity is expected to result in additional revenue growth in the long term. In the near term, revenue growth lags behind the increased expenses for market development, such as hiring and training of new sales representatives and surgeon education programs.

Results of Operations

Comparison of the Three Months Ended June 30, 2016 and 2015

Revenues

Revenues for the three months ended June 30, 2016 increased 61.8% to approximately $10,382,000 as compared to approximately $6,417,000 for the three months ended June 30, 2015. This increase was primarily a result of our strategy of focusing largely on growing product usage in our active accounts and to a lesser extent the development of new accounts. A new account can become an active account in a six month period with repeat orders and increased utilization. As such, revenue growth primarily occurs from increased purchasing from active accounts, followed by revenue growth from new accounts. Each new period of measurement is thus benefited from growth in active accounts which may include those that were new accounts in the prior measurement period. Finally, AxoGen recognized approximately $32,000 and $128,000 of grant revenue for the three months ended June 30, 2016 and 2015, which decrease is a result of grants maturing and less activity being associated with them that can be billed by the Company.

Gross Profit

Gross profit for the three months ended June 30, 2016 increased 64.5% to approximately $8,847,000 as compared to approximately $5,377,000 for the three months ended June 30, 2015. Such increase in aggregate dollars was primarily attributable to the increased revenues in the second quarter of 2016, and to a lesser extent by an improvement in gross margin. Gross margin improved to 85.2% for the three months ended June 30, 2016 as compared to 83.8% for the same period in 2015 as a result of processing efficiencies and favorable product mix as a result of changes both within and between product lines as gross profit differs by product.

Table of Contents

Costs and Expenses

Total cost and expenses increased 38.8% to approximately $10,453,000 for the three months ended June 30, 2016 as compared to approximately $7,531,000 for the three months ended June 30, 2015. These increases were due primarily to increased sales and marketing activities and costs associated with increased revenue, along with an increase in employee compensation expenses and research and development costs as the Company enrolls patients in its clinical trial for the Avance® Nerve Graft.

Sales and marketing expenses increased 40.9% to approximately $6,780,000 for the three months ended June 30, 2016 as compared to approximately $4,812,000 for the three months ended June 30, 2015. This increase was due primarily to the costs associated with the continued expansion of our direct sales force and surgeon education programs, and to a lesser extent increased support for both our direct sales force and independent distributors. As a percentage of revenues, sales and marketing expenses were 65.3% for the three months ended June 30, 2016 compared to 75.0% for the three months ended June 30, 2015. Such lower sales and marketing expenses as a percentage of revenue were a result of the revenue increase outpacing increases in costs and expenses.

General and administrative expenses increased 38.0% to approximately $2,736,000 for the three months ended June 30, 2016 as compared to approximately $1,982,000 for the three months ended June 30, 2015. Such increase was primarily a result of increased expenses related to employee compensation, which included a $272,240 non-cash charge related to contingent stock options for which the contingency was satisfied as a result of the approval of the Amendments to the 2010 Stock Incentive Plan at the annual shareholder meeting in May 2016, and professional service fees. Also contributing, to a lesser extent, to the rise in such general and administrative expenses was an increase in bank charges related to sales activity and travel expenses offset by a reduction in certain outside service costs. As a percentage of revenues, general and administrative expenses were 26.4% for the three months ended June 30, 2016 as compared to 30.9% for the three months ended June 30, 2015. Such lower general and administrative expenses as a percentage of revenue were a result of the revenue increase outpacing increases in costs and expenses.

Research and development expenses increased approximately 27.3% to approximately $937,000 for the three months ended June 30, 2016 as compared to approximately $736,000 for the three months ended June 30, 2015. Research and development costs include AxoGen’s product development and clinical efforts including the Multicenter, Prospective, Randomized, Subject and Evaluator Blinded Comparative Study of Nerve Cuffs and Avance® Nerve Graft Evaluating Recovery Outcomes for the Repair of Nerve Discontinuities (“RECON”) study, the phase 3 trial to support the Company’s Biologic License Application (“BLA”). This activity varies from quarter to quarter due to the timing of certain projects and enrollment in RECON. The increase in expenses for 2016 relate to expenditures for RECON and hiring additional personal to support both RECON and product development activity, offset by reduced costs of the Company’s RANGER® Registry and certain projects that have been completed or are near completion. It is expected that costs associated with RECON will continue to increase as more subjects are enrolled in the trial over approximately the next two years and activity increases to prepare and submit the BLA at the completion of RECON. Although AxoGen’s products are developed for sale in their current use, it does conduct research and product development efforts focused on new products and new applications for existing products. AxoGen is active in pursuing research grants to support this research. The Company’s product pipeline development also contributed to a portion of the research and development expenses in 2016, with grant revenue offsetting a portion of this activity. Grant revenue has been decreasing as grants have matured and there can be no assurance that new grants providing additional grant revenue will be obtained. As a percentage of revenues, research and development expenses for the three months ended June 30, 2016 were 9.0% as compared to 11.5% for the three months ended June 30, 2015.

Other Income and Expenses

Interest expense increased 13.6% to approximately $1,163,000 for the three months ended June 30, 2016 as compared to approximately $1,024,000 for the three months ended June 30, 2015. This increase was due to the difference in the interest generated by increased revenues related to the Revenue Interest Agreement with Three Peaks. As a result of the accounting treatment for the Three Peaks transaction, interest expense included approximately $99,000 and $177,000 for the three months ended June 30, 2016 and 2015, respectively, of non-cash expense that is based upon the terms of the Three Peaks transaction and increases in AxoGen revenues. Other than the $99,000 and $177,000 non-cash expense, the

Table of Contents

remaining $1,064,000 and $847,000 in interest expense for the three months ended June 30, 2016 and 2015, respectively, is related to cash paid for interest on the Term Loan Agreement.

Income Taxes

The Company had no income tax expenses or income tax benefit for each of the three months ended June 30, 2016 and 2015 due to incurrence of net operating loss in each of these periods.

Comparison of the Six Months Ended June 30, 2016 and 2015:

Revenues

Revenues for the six months ended June 30, 2016 increased 62.7% to approximately $18,494,000 as compared to approximately $11,369,000 for the six months ended June 30, 2015. This increase was primarily a result of our strategy of focusing largely on growing product usage in our active accounts and to a lesser extent the development of new accounts. A new account can become an active account in a six month period with repeat orders and increased utilization. As such, revenue growth primarily occurs from increased purchasing from active accounts, followed by revenue growth from new accounts. Each new period of measurement is thus benefited from growth in active accounts which may include those that were new accounts in the prior measurement period. Finally, AxoGen recognized approximately $78,000 and $270,000 of grant revenue for the six months ended June 30, 2016 and 2015, which decrease is a result of grants maturing and less activity being associated with them that can be billed by the Company.

Gross Profit

Gross profit for the six months ended June 30, 2016 increased 66.4% to approximately $15,554,000 as compared to approximately $9,346,000 for the six months ended June 30, 2015. Such increase in aggregate dollars was primarily attributable to the increased revenues in the first six months of 2016, and to a lesser extent by an improvement in gross margin. Gross margin improved to 84.1% for the six months ended June 30, 2016 as compared to 82.2% for the same period in 2015 as a result of processing efficiencies and changes in product mix as a result of changes both within and between product lines as gross profit differs by product.

Costs and Expenses

Total cost and expenses increased 40.9% to approximately $19,782,000 for the six months ended June 30, 2016 as compared to approximately $14,043,000 for the six months ended June 30, 2015. These increases were due primarily to increased sales and marketing activities along with increases in employee compensation. These increases were also attributable to expenses associated with being a public company, facility costs and research and development costs associated with the Company’s preparation for, and start of, its clinical trial for Avance® Nerve Graft.

Sales and marketing expenses increased 48.5% to approximately $12,986,000 for the six months ended June 30, 2016 as compared to approximately $8,745,000 for the six months ended June 30, 2015. This increase was due primarily to the costs associated with the continued expansion of the direct sales force and surgeon education programs, and to a lesser extent increased support for both AxoGen’s direct sales force and independent distributors. As a percentage of revenues, sales and marketing expenses were 70.2% for the six months ended June 30, 2016 compared to 76.9% for the six months ended June 30, 2015. Such lower sales and marketing expenses as a percentage of revenue were a result of the revenue increase outpacing increases in costs and expenses.

General and administrative expenses increased 25.4% to approximately $4,881,000 for the six months ended June 30, 2016 as compared to approximately $3,891,000 for the six months ended June 30, 2015. The increase was primarily a result of increased expenses related to employee compensation, which included a $272,240 non-cash charge related to contingent stock options for which the contingency was satisfied as a result of the approval of the Amendments to the 2010 Stock Incentive Plan at the annual shareholder meeting in May 2016, and professional service fees. Bank charges related to sales activity also increased, offset by a reduction in certain outside service costs. As a percentage of revenues, general and administrative expenses were 26.4% for the six months ended June 30, 2016 as compared to 34.2% for the six months ended June 30, 2015. Such lower general and administrative expenses as a percentage of revenue were a result of the revenue increase outpacing increases in costs and expenses.

Table of Contents

Research and development costs increased 36.1% to approximately $1,915,000 in the six months ended June 30, 2016 as compared to approximately $1,407,000 for the six months ended June 30, 2015. Research and development costs include AxoGen’s product development and clinical efforts including the Multicenter, Prospective, Randomized, Subject and Evaluator Blinded Comparative Study of Nerve Cuffs and Avance® Nerve Graft Evaluating Recovery Outcomes for the Repair of Nerve Discontinuities (“RECON”) study, the phase 3 trial to support the Company’s Biologic License Application (“BLA”). This activity varies from quarter to quarter due to the timing of certain projects and enrollment in RECON. The increase in expenses for 2016 relate to expenditures for RECON and hiring additional personal to support both RECON and product development activity, offset by reduced costs of the Company’s RANGER® Registry and certain projects that have been completed or are near completion. It is expected that costs associated with RECON will continue to increase as more subjects are enrolled in the trial over approximately the next two years and activity increases to prepare and submit the BLA at the completion of RECON. Although AxoGen’s products are developed for sale in their current use, it does conduct research and product development efforts focused on new products and new applications for existing products. AxoGen is active in pursuing research grants to support this research. The Company’s product pipeline development also contributed to a portion of the research and development expenses in 2016, with grant revenue offsetting a portion of this activity. Grant revenue has been decreasing as grants have matured and there can be no assurance that new grants providing additional grant revenue will be obtained. As a percentage of revenues, research and development expenses for the six months ended June 30, 2016 were 10.4% as compared to 12.4% for the six months ended June 30, 2015.

Other Income and Expenses

Interest expense increased 7.3% to approximately $2,166,000 for the six months ended June 30, 2016 as compared to approximately $2,019,000 for the six months ended June 30, 2015. This increase was due to the difference in the interest generated by increased revenues related to the Revenue Interest Agreement with Three Peaks. As a result of the accounting treatment for the Three Peaks transaction, interest expense included approximately $202,000 and $369,000 for the six months ended June 30, 2016 and 2015, respectively, of non-cash expense that is based upon the terms of the Three Peaks transaction and increases in AxoGen revenues. Other than the $202,000 and $369,000 non-cash expense, the remaining $1,964,000 and $1,650,000 in interest expense for the six months ended June 30, 2016 and 2015, respectively, is related to cash paid for interest on the Term Loan Agreement.

Income Taxes

The Company had no income tax expenses or income tax benefit for each of the six months ended June 30, 2016 and 2015 due to incurrence of net operating loss in each of these periods.

Effect of Inflation

Inflation has not had a significant impact on the Company’s operations or cash flow during 2016 or the fiscal years ended 2015 or 2014.

Liquidity and Capital Resources

Term Loan Agreement and Revenue Interest Agreement

On November 12, 2014, AxoGen, as borrower, and AC, as guarantor, entered into the Term Loan Agreement with the lenders party thereto and Three Peaks, as administrative and collateral agent for the lenders party thereto. Under the Term Loan Agreement, Three Peaks has agreed to lend to AxoGen the Initial Term Loan which has a six year term and requires interest only payments and a final principal payment due at the end of the term. Interest is payable quarterly at 9.00% per annum plus the greater of LIBOR or 1.0% which as of the Initial Closing Date resulted in a 10% interest rate. Under certain conditions, as provided in the Term Loan Agreement, as amended by the Term Loan Agreement Amendment, AxoGen has the option to draw an additional $7 million as a Subsequent Borrowing during the period of July 1, 2016 through September 30, 2016 under similar terms and conditions. AxoGen has to comply with certain covenants including limiting new indebtedness, restricting the payment of dividends and maintaining certain levels of revenue. Three Peaks has a first perfected security interest in the assets of AxoGen.

Table of Contents

In addition, AxoGen entered into a 10 year Revenue Interest Agreement with Three Peaks. Royalty payments are based on a royalty rate of 3.75% of AxoGen’s revenues up to a maximum of $30 million in revenues in any 12 month period. In the event the Subsequent Borrowing is drawn, the royalty rate increases proportionally up to a maximum of 4.80%. AxoGen has to comply with certain covenants including those covenants under the Term Loan.

Under the Term Loan Agreement, AxoGen has the option at any time to prepay the Term Loan, in whole or in part, and the Royalty Interest Agreement by making the following payment, and Three Peaks has the right to demand the following payment upon a change of control of AxoGen, sale of a majority of AxoGen’s assets or a material adverse change to AxoGen: (i) on or prior to the first anniversary of the applicable Closing Date, 120% of the outstanding principal amount of the Term Loan or any portion being prepaid; (ii) after the first anniversary but no later than the second anniversary of the applicable Closing Date, 135% of the outstanding principal amount of the Term Loan or any portion being prepaid; (iii) after the second anniversary but no later than the third anniversary of the applicable Closing Date, 150% of the outstanding principal amount of the Term Loan or any portion being prepaid; or (iv) after the third anniversary of the applicable Closing Date, an amount generating an internal rate of return of 16.25% of the outstanding principal amount of the Term Loan or any portion being prepaid. In all cases, the amount due is reduced by the sum of interest and principal previously paid and all amounts received under the Revenue Interest Agreement. In each such case AxoGen will also owe an additional 3% of the originally advanced Term Loan amount. Upon payment to Three Peaks, AxoGen would have no further obligations to Three Peaks under the Term Loan or the Revenue Interest Agreement.

In connection with the Term Loan Agreement, on the Signing Date, the Company and AC entered into the Security Agreement with Three Peaks, pursuant to which each of the Company and AC grants to Three Peaks a security interest in certain collateral as specified in the Security Agreement to guarantee the payment in full when due of the secured obligations. In the event of default per the terms of the Term Loan Agreement, Three Peaks would have the ability to foreclose on the pledged collateral and the Company and AC would not be able to continue its current business if such foreclosure occurred.

Also in connection with the above transaction, the Company sold 1,375,969 shares of its common stock to Three Peaks for a total of $3.55 million at a price of $2.58 per share. Pursuant to the equity purchase provisions in the Three Peaks Term Loan Agreement, in the event that prior to November 12, 2016, we sell our securities at a lower price per share than the $2.58 per share paid by Three Peaks, or where the terms of such subsequent sale are otherwise more favorable, then in such case we have agreed to match the more favorable terms of such subsequent sale with respect to the shares purchased by Three Peaks. A subsequent sale does not include the issuance of securities or options to our employees, officers, directors or consultants pursuant to our approved employee option pool or any other employee stock purchase or option plan existing as of November 12, 2014.

As a result of the accounting treatment for the Three Peaks transaction, interest expense included approximately $99,000 and $177,000 for the three months ended June 30, 2016 and 2015, respectively, and approximately $202,000 and $369,000 for the six months ended June 30, 2016 and 2015, respectively, of non-cash expense that is based upon the terms of the Three Peaks transaction and increases in AxoGen revenues. Other than the $202,000 and $369,000 non-cash expense, the remaining $1,964,000 and $1,650,000 in interest expense for the six months ended June 30, 2016 and 2015, respectively, is related to cash paid for interest on the Term Loan Agreement.

The Company had no material commitments for capital expenditures at June 30, 2016.

Table of Contents

Public Offering of Common Stock

On February 5, 2015, AxoGen entered into an underwriting agreement with the Underwriter in connection with the February 2015 Offering. The Company also granted to the Underwriter a 30-day option to purchase up to an aggregate of 709,200 additional shares of its common stock to cover over-allotments, if any.

On August 26, 2015, the Company entered into the Purchase Agreement with ESSEX WOODLANDS for the purchase of 4,861,111 shares of the Company’s common stock at a public offering price of $3.60 per share, raising approximately $17.5 million in gross proceeds before deducting expenses related to the August 2015 Offering. The expenses directly related to the August 2015 Offering were approximately $300,000 and were paid by the Company. Such expenses include the Company’s legal and accounting fees, printing expenses, transfer agent fees and miscellaneous fees and costs related to the August 2015 Offering. Proceeds from the August 2015 Offering will be used for sales and marketing and general working capital purposes. The Company has provided certain demand and “piggy-back” registration rights in connection with this sale of the Company’s common stock. The August 2015 Offering was made pursuant to the Company’s effective shelf registration statement on Form S-3 (Registration No. 333-195588) previously filed with the SEC on April 30, 2014, and pursuant to the prospectus supplement and the accompanying prospectus describing the terms of the August 2015 Offering, dated August 26, 2015.

Cash Flow Information

AxoGen had working capital of approximately $25.82 million and a current ratio of 7.58 at June 30, 2016, compared to working capital of $31.34 million and a current ratio of 9.45 at December 31, 2015. The decrease in working capital and the current ratio at June 30, 2016 as compared to December 31, 2015 was due primarily to the use of working capital to fund operations, including the purchase of certain equipment related to the distribution and processing facilities. The Company believes it has sufficient cash resources to meet its liquidity requirements for at least the next 12 months.

AxoGen’s future capital requirements depend on a number of factors, including, without limitation, continued adoption of our products by surgeons and growth of our revenues, continued expansion and development of our direct sales force, expenses associated with our professional education programs, maintaining our gross margins, expenses related to our facilities for production and distribution of products and general market conditions. AxoGen could face increasing capital needs depending on the extent to which AxoGen is unable to increase revenues.

If AxoGen needs additional capital in the future, it may raise additional funds through public or private equity offerings, debt financings or from other sources. The sale of additional equity would result in dilution to AxoGen’s shareholders. There is no assurance that AxoGen will be able to secure funding on terms acceptable to it, or at all. The increasing need for capital could also make it more difficult to obtain funding through either equity or debt. Should additional capital not become available to AxoGen as needed, AxoGen may be required to take certain actions, such as, slowing sales and marketing expansion, delaying regulatory approvals or reducing headcount.

During the six months ended June 30, 2016, the Company had a net decrease in cash and cash equivalents of approximately $7,636,000 as compared to a net increase of cash and cash equivalents of approximately $7,407,000 for the six months ended June 30, 2015. The Company’s principal sources and uses of funds are explained below:

Cash used in operating activities

The Company used approximately $7,406,000 of cash for operating activities for the six months ended June 30, 2016, as compared to using approximately $6,011,000 of cash for operating activities for the six months ended June 30, 2015.

Table of Contents

This increase in cash used in operating activities is primarily attributable to the increase in accounts receivable, inventory and prepaid expenses accompanied by the net loss generated for the three months ended June 30, 2016, offset by the increase in our accounts payable and accrued expenses.

Cash used for investing activities

Investing activities for the six months ended June 30, 2016 used approximately $554,000 of cash as compared to using approximately $187,000 of cash for the six months ended June 30, 2015. This increase in use is principally attributable to the non-recurrence of purchases of certain fixed assets for the expansion of the worldwide distribution facility in Burleson, Texas and purchase of certain fixed assets for the new processing facility in Dayton, Ohio.

Cash provided by financing activities

Financing activities for the six months ended June 30, 2016 provided approximately $324,000 of cash as compared to providing approximately $13,605,000 of cash for the six months ended June 30, 2015. The cash provided in the six months ended June 30, 2015 was due to proceeds received from the February 2015 Offering.

Off-Balance Sheet Arrangements

AxoGen does not have any off-balance sheet arrangements.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not Applicable.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

The Company maintains “disclosure controls and procedures” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (the “Exchange Act”), that are designed to ensure that information required to be disclosed by us in reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, and Board of Directors, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, management recognizes that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable assurance of achieving the desired objectives, and we necessarily are required to apply our judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures.

Our management, including our principal executive officer and principal financial officer, evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of June 30, 2016 and concluded that our disclosure controls and procedures were effective.

Changes in Internal Controls Over Financial Reporting

During the six months ended June 30, 2016, there were no changes in the Company’s internal control over financial reporting (as defined in Rule 13a-15(f) and 15d–15(f) under the Exchange Act) that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

Table of Contents

UNITED STATES

PART II –OTHER INFORMATION

ITEM 1 – LEGAL PROCEEDINGS

From time to time, we may be a party to various lawsuits, claims and other legal proceedings that arise in the ordinary course of our business, some of which relate to some or all of certain of our patents. While it is not possible to determine the outcome of these matters, management does not expect that the ultimate costs to resolve these matters will materially adversely affect our business, financial position, or results of operations.

The Company is not a party to any material litigation as of June 30, 2016.

ITEM 1A - RISK FACTORS

The Company faces a number of risks and uncertainties. In addition to the other information in this report and the Company’s other filings with the SEC, readers should consider carefully the risk factors discussed in Part I “Item 1A. Risk Factors” in the Company’s Annual Report on Form 10-K as of and for the year ended December 31, 2015. There have been no material changes to these risk factors. If any of these risks actually occur, the Company’s business, results of operations or financial condition could be materially adversely affected.

ITEM 2 - UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3 - DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4 - MINE SAFETY DISCLOSURES

Not Applicable.

ITEM 5 - OTHER INFORMATION

None

Table of Contents

ITEM 6 - EXHIBITS


Exhibit Number		Description

10.1*		Amendment No. 3 to Employment Agreement, effective as of June 1, 2016, by and between Gregory G. Freitag and AxoGen, Inc. (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on May 31, 2016).

10.2		Amendment 1 to Term Loan Agreement, dated as of June 29, 2016, by and among AxoGen, Inc., AxoGen Corporation, Three Peaks Capital S.a.r.l. and Oberland Capital Healthcare Master Fund LP. (incorporated by reference to Exhibit 10.18.4 to the Company’s Current Report on Form 8-K filed on July 6, 2016).

10.3		Second Amendment to the Amended and Restated Standard Exclusive License Agreement No. A5140, dated as of July 5, 2016, by and between AxoGen Corporation and the University of Florida Research Foundation, Inc. (incorporated by reference to Exhibit 10.2.1 to the Company’s Current Report on Form 8-K filed on July 11, 2016).

31.1†		Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2†		Certification of Principle Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32††		Certification Pursuant to 18 U.S.C. §1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS		XBRL Instance Document.

101.SCH		XBRL Taxonomy Extension Schema Document.

101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document.

101.DEF		XBRL Taxonomy Extension Definition Linkbase Document.

101.LAB		XBRL Extension Labels Linkbase.

101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document.

* Management contract or compensatory plan or arrangement.

† Filed herewith.

†† Furnished herewith.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


		AXOGEN, INC.


Dated August 3, 2016		/s/ Karen Zaderej
		Karen Zaderej
		Chief Executive Officer
		(Principal Executive Officer)


		/s/ Peter J. Mariani
		Peter J. Mariani
		Chief Financial Officer
		(Principal Financial and Accounting Officer)

Table of Contents

EXHIBIT INDEX


Exhibit Number		Description

10.1*		Amendment No. 3 to Employment Agreement, effective as of June 1, 2016, by and between Gregory G. Freitag and AxoGen, Inc. (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on May 31, 2016).

10.2		Amendment 1 to Term Loan Agreement, dated as of June 29, 2016, by and among AxoGen, Inc., AxoGen Corporation, Three Peaks Capital S.a.r.l. and Oberland Capital Healthcare Master Fund LP. (incorporated by reference to Exhibit 10.18.4 to the Company’s Current Report on Form 8-K filed on July 6, 2016).

10.3		Second Amendment to the Amended and Restated Standard Exclusive License Agreement No. A5140, dated as of July 5, 2016, by and between AxoGen Corporation and the University of Florida Research Foundation, Inc. (incorporated by reference to Exhibit 10.2.1 to the Company’s Current Report on Form 8-K filed on July 11, 2016).

31.1†		Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2†		Certification of Principle Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32††		Certification Pursuant to 18 U.S.C. §1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS		XBRL Instance Document.

101.SCH		XBRL Taxonomy Extension Schema Document.

101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document.

101.DEF		XBRL Taxonomy Extension Definition Linkbase Document.

101.LAB		XBRL Extension Labels Linkbase.

101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document.

* Management contract or compensatory plan or arrangement.

† Filed herewith.

†† Furnished herewith.

EX-31.1 2 axgn-20160630ex311c08e7a.htm EX-31.1 Ex_311

EXHIBIT 31.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Karen Zaderej, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of AxoGen, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


Date: August 3, 2016
	/s/ Karen Zaderej
	Karen Zaderej
	Chief Executive Officer

EX-31.2 3 axgn-20160630ex3121d400b.htm EX-31.2 Ex_312

EXHIBIT 31.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Peter J. Mariani, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of AxoGen, Inc.;

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


Date: August 3, 2016
	/s/ Peter J. Mariani
	Peter J. Mariani
	Chief Financial Officer

EX-32 4 axgn-20160630xex32.htm EX-32 Ex_32

EXHIBIT 32

CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (SUBSECTIONS (A) AND (B) OF SECTION 1350, CHAPTER 63 OF TITLE 18, UNITED STATES CODE)

In connection with the Quarterly Report on Form 10-Q (the “Report”) of AxoGen, Inc. (the “Company”), Karen Zaderej, Chief Executive Officer of the Company and Peter J. Mariani, Chief Financial Officer of the Company, each certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of her/his knowledge that:

1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Dated: August 3, 2016
	/s/ Karen Zaderej
	Karen Zaderej
	Chief Executive Officer
	(Principal Executive Officer)


	/s/ Peter J. Mariani
	Peter J. Mariani
	Chief Financial Officer
	(Principal Financial Officer)

EX-101.INS 5 axgn-20160630.xml EX-101.INS 0000805928 axgn:StockOptionsContingencyConditionApprovedMember 2015-08-01 2016-03-31 0000805928 us-gaap:EmployeeStockOptionMember 2016-04-01 2016-06-30 0000805928 axgn:StockOptionsContingencyConditionApprovedMember 2016-04-01 2016-06-30 0000805928 us-gaap:EmployeeStockOptionMember 2016-01-01 2016-06-30 0000805928 us-gaap:EmployeeStockOptionMember 2015-04-01 2015-06-30 0000805928 us-gaap:EmployeeStockOptionMember 2015-01-01 2015-06-30 0000805928 axgn:ThreePeaksCapitalMember axgn:RevenueInterestPurchaseAgreementMember us-gaap:MaximumMember 2014-11-12 2014-11-12 0000805928 us-gaap:SellingAndMarketingExpenseMember 2016-04-01 2016-06-30 0000805928 us-gaap:SellingAndMarketingExpenseMember 2016-01-01 2016-06-30 0000805928 us-gaap:SellingAndMarketingExpenseMember 2015-04-01 2015-06-30 0000805928 us-gaap:SellingAndMarketingExpenseMember 2015-01-01 2015-06-30 0000805928 us-gaap:LeaseholdImprovementsMember 2016-06-30 0000805928 us-gaap:EquipmentMember 2016-06-30 0000805928 axgn:FurnitureAndOfficeEquipmentMember 2016-06-30 0000805928 us-gaap:LeaseholdImprovementsMember 2015-12-31 0000805928 us-gaap:EquipmentMember 2015-12-31 0000805928 axgn:FurnitureAndOfficeEquipmentMember 2015-12-31 0000805928 axgn:SecuritiesPurchaseAgreementMember 2015-08-26 2015-08-26 0000805928 axgn:SHNMedicalOfficePropertiesTrustMember 2016-06-30 0000805928 axgn:TermLoanAndRevenueInterestPurchaseAgreementMember 2016-06-30 0000805928 axgn:TermLoanAndRevenueInterestPurchaseAgreementMember 2015-12-31 0000805928 axgn:LicenseAndServicesAgreementMember 2016-01-01 2016-06-30 0000805928 us-gaap:PatentsMember 2016-06-30 0000805928 us-gaap:LicensingAgreementsMember 2016-06-30 0000805928 us-gaap:PatentsMember 2015-12-31 0000805928 us-gaap:LicensingAgreementsMember 2015-12-31 0000805928 us-gaap:EmployeeStockOptionMember 2016-06-30 0000805928 axgn:Axogen401kPlanMember 2016-04-01 2016-06-30 0000805928 axgn:AccountingStandardsUpdate201503Member us-gaap:LongTermDebtMember 2016-06-30 0000805928 axgn:AccountingStandardsUpdate201503Member us-gaap:OtherAssetsMember 2015-12-31 0000805928 axgn:AccountingStandardsUpdate201503Member us-gaap:LongTermDebtMember 2015-12-31 0000805928 axgn:ThreePeaksCapitalMember axgn:RevenueInterestPurchaseAgreementMember 2014-11-12 2014-11-12 0000805928 axgn:ThreePeaksCapitalMember axgn:TermLoanMember 2016-06-30 0000805928 axgn:ThreePeaksCapitalMember axgn:TermLoanMember 2015-12-31 0000805928 axgn:ThreePeaksCapitalMember axgn:TermLoanMember 2014-11-13 0000805928 axgn:EssexWoodlandsFundIxL.p.Member axgn:SecuritiesPurchaseAgreementMember 2015-08-26 0000805928 axgn:IPOAndOverAllotmentOptionMember 2015-02-13 0000805928 us-gaap:OverAllotmentOptionMember 2015-02-05 0000805928 us-gaap:IPOMember 2015-02-05 0000805928 axgn:ThreePeaksCapitalMember 2014-11-12 0000805928 2015-06-30 0000805928 2014-12-31 0000805928 2016-04-01 2016-06-30 0000805928 2015-04-01 2015-06-30 0000805928 2015-01-01 2015-06-30 0000805928 2015-12-31 0000805928 2016-08-03 0000805928 2016-01-01 2016-06-30 0000805928 axgn:ThreePeaksCapitalMember axgn:TermLoanMember 2014-11-12 0000805928 axgn:ThreePeaksCapitalMember axgn:RevenueInterestPurchaseAgreementMember us-gaap:MaximumMember 2014-11-12 0000805928 axgn:ThreePeaksCapitalMember axgn:RevenueInterestPurchaseAgreementMember 2014-11-12 0000805928 us-gaap:LicensingAgreementsMember us-gaap:MinimumMember 2016-01-01 2016-06-30 0000805928 axgn:EssexWoodlandsFundIxL.p.Member axgn:SecuritiesPurchaseAgreementMember 2015-08-26 2015-08-26 0000805928 axgn:IPOAndOverAllotmentOptionMember 2015-02-13 2015-02-13 0000805928 us-gaap:LicensingAgreementsMember us-gaap:MaximumMember 2016-01-01 2016-06-30 0000805928 us-gaap:OverAllotmentOptionMember 2015-02-05 2015-02-05 0000805928 axgn:LicenseAndServicesAgreementMember 2015-08-06 2015-08-06 0000805928 us-gaap:PatentsMember 2016-01-01 2016-06-30 0000805928 us-gaap:LicensingAgreementsMember 2016-01-01 2016-06-30 0000805928 2016-06-30 0000805928 axgn:Axogen401kPlanMember 2016-01-01 2016-06-30 0000805928 axgn:Axogen401kPlanEmployerMatchingContributionTranche2Member 2016-01-01 2016-06-30 0000805928 axgn:Axogen401kPlanEmployerMatchingContributionTranche1Member 2016-01-01 2016-06-30 0000805928 axgn:ThreePeaksCapitalMember axgn:TermLoanMember us-gaap:ScenarioForecastMember 2016-07-01 2016-09-30 0000805928 axgn:ThreePeaksCapitalMember axgn:TermLoanMember 2014-11-12 2014-11-12 0000805928 axgn:SHNMedicalOfficePropertiesTrustMember 2016-03-16 0000805928 us-gaap:FinancingReceivablesEqualToGreaterThan90DaysPastDueMember 2016-06-30 0000805928 us-gaap:FinancingReceivables60To89DaysPastDueMember 2016-06-30 0000805928 us-gaap:FinancingReceivablesEqualToGreaterThan90DaysPastDueMember us-gaap:MinimumMember 2016-01-01 2016-06-30 0000805928 us-gaap:FinancingReceivables60To89DaysPastDueMember us-gaap:MinimumMember 2016-01-01 2016-06-30 0000805928 us-gaap:FinancingReceivables60To89DaysPastDueMember us-gaap:MaximumMember 2016-01-01 2016-06-30 0000805928 us-gaap:MinimumMember 2016-01-01 2016-06-30 0000805928 axgn:SHNMedicalOfficePropertiesTrustMember 2016-03-16 2016-03-16 iso4217:USD xbrli:shares xbrli:shares axgn:item iso4217:USD utr:sqft xbrli:pure P3Y P5Y P60D P90D P61D P90D 0.05 0.20 7050 0.010 7000000 0.03 0.02 0.05 18 60000 64000 64000 2000 25000 10000 15000 12500 267387 P18M P60D P2Y P30D 0.0375 15000000 17500000 1.00 0.03 0.01 0.0375 0.0480 P5Y 0.03 0.1625 1.35 1.50 1.20 false --12-31 Q2 2016 2016-06-30 10-Q 0000805928 30132224 Yes Smaller Reporting Company AxoGen, Inc.

3695127

3893834

2090874

1863349

4782989

6072121

1589070

1672264

1938346

2105936

111368424

112443288

192000

241000

64957

63506

64956

31210

63506

32696

22710

11000

32033

16000

11761

36700326

31750737

35051374

29747157

8215791

15622932

25909500

18273203

7407141

-7636297

<div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> 10.  Commitments and Contingencies   Commercial Lease On March 16, 2016, AC entered into the Fourth Amendment to Lease (“Fourth Amendment”) with SNH Medical Office Properties Trust, a Maryland real estate investment trust (“SNH”).  SNH is the landlord of AC’s currently leased 11,761 square foot corporate headquarters facility in Alachua, Florida (the “Current Premises”) pursuant to that certain lease dated as of February 6, 2007, as amended (the “Lease”).   The Fourth Amendment expands the Current Premises by 7,050 square feet (the “Expansion Premises”).  The Fourth Amendment also provides that the Expiration Date (as defined in the Fourth Amendment) of the Lease will be extended to approximately five years from the Occupancy Date (as defined in the Fourth Amendment) of the Expansion Premises, which Occupancy Date is occurred in June 2016.  The original expiration date of the Current Premises remains unchanged; provided, however, that AC shall have the right to extend the Current Premises Term (as defined in the Fourth Amendment) for three additional periods (the “Current Premises Extended Term”), the first such Current Premises Extended Term to commence on November 1, 2018 and end on October 31, 2019, the second such Current Premises Extended Term to commence on November 1, 2019 and end on October 31, 2020, and the third such Current Premises Extended Term to commence on November 1, 2020 and end on the Expiration Date.  AC also has the right to extend the term of the then current Leased Premises (as defined in the Fourth Amendment) for an additional period of five years commencing on the day immediately after the Expiration Date.  AC’s additional annual cost of the Expansion Premises will be approximately $123,000,  $127,000,  $131,000,  $135,000 and $139,000 for years one through five, respectively, of the Lease, with year one commencing on the Occupancy Date.   Processing Agreement Until February 2016, the Company was party to that certain Amended and Restated Nerve Tissue Processing Agreement (the “LifeNet Agreement”) with LifeNet Health (“LifeNet”), whereby the Company processed and packaged Avance® Nerve Graft using its employees and equipment located at LifeNet in Virginia Beach, Virginia (the “Virginia Beach Facility”).  As a result of business requirements of LifeNet and their need for additional space, on April 16, 2015 LifeNet notified the Company that it would need to transition out of the Virginia Beach Facility and the LifeNet Agreement was terminated effective February 27, 2016.     As a result of the termination of the LifeNet Agreement, on August 6, 2015 the Company entered into a License and Services Agreement (the “CTS Agreement”) with Community Blood Center (d/b/a Community Tissue Services) (“CTS”) whose headquarters are located in Dayton, Ohio.  The CTS facility and CTS Agreement provides the Company a cost effective, quality controlled and licensed facility to process and package its Avance® Nerve Graft using the Company’s employees and processing equipment. The processing that was performed at the Virginia Beach Facility has been transferred in its entirety to the CTS facility.     The CTS Agreement is for a five-year term, subject to earlier termination by either party for cause, or after the two-year anniversary of the CTS Agreement without cause, upon 18 months notice. Under the CTS Agreement, the Company pays CTS a facility fee for clean room/processing, storage and office space and CTS provides services in support of the Company’s processing such as routine sterilization of daily supplies, providing disposable supplies, microbial services and office support.  The service fee is based on a per donor batch rate.  However, AxoGen could reproduce a manufacturing space that would meet its needs if it no longer continued its relationship with CTS.  AxoGen’s processing methods and process controls have been developed and validated to ensure product uniformity and quality.  Pursuant to the CTS Agreement, AxoGen pays license fees on a monthly basis to CTS which total an annual amount of approximately $416,000.      </div><div style="margin-left:0%;margin-right:0%;"> </div><div style="margin-left:0%;margin-right:0%;"></div> </div>

0.01

50000000

1375969

4728000

709200

5437200

4861111

29984591

30128099

29984591

30128099

3550000

299846

301281

2022722

1039841

2940003

1534412

14042820

7530681

19782413

10453441

25000000

LIBOR

0.10

0.0900

P10Y

P6Y

846000

-846000

782000

14118

28593

93797

83006

171401

92145

1.00

0.50

87610

167590

-0.29

-0.13

-0.22

-0.09

2959000

1400000

399509

431542

32000

64000

897594

179997

907545

267387

678082

743390

P3Y

P20Y

P17Y

3890602

1982020

4881012

2736255

9345847

5377412

15553639

8847471

976928

198707

965715

1337732

-10791

3684

326337

852362

131739

190586

<div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> 5.    Intangible Assets   The Company’s intangible assets consist of the following:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:75.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:75.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30, </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31, </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> </tr> <tr> <td valign="bottom" style="width:75.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:75.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.58%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:75.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> License agreements </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>907,545 </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>897,594 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:75.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Patents </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>267,387 </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>179,997 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:75.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Less: accumulated amortization </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(431,542) </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(399,509) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:75.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Intangible assets, net </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.58%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>743,390 </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.58%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>678,082 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   License agreements are being amortized over periods ranging from 17-20 years. Patent costs were being amortized over three years. As of June 30, 2016, the patents were fully amortized, and the remaining patents of $267,387 were pending patent costs and were not amortizable. Amortization expense was approximately $16,000 and $11,000 for the three months ended June 30, 2016 and 2015, respectively, and approximately $32,000 and $23,000 for the six months ended June 30, 2016 and 2015, respectively. As of June 30, 2016, future amortization of license agreements for the remainder of this year and the next seven years is expected to be $32,000 for 2016, $64,000 for 2017 through 2022 and $60,000 for 2023.   License Agreements   The Company has entered into multiple license agreements (the “License Agreements”) with the University of Florida Research Foundation and the University of Texas at Austin. Under the terms of the License Agreements, the Company acquired exclusive worldwide licenses for underlying technology used in repairing and regenerating nerves. The licensed technologies include the rights to issued patents and patents pending in the United States and international markets. The effective term of the License Agreements extends through the term of the related patents and the agreements may be terminated by the Company with 60 days prior written notice. Additionally, in the event of default, licensors may terminate an agreement if the Company fails to cure a breach after written notice. The License Agreements contain the key terms listed below:   <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"></td><td valign="top" align="left" style="width: 17.00pt; display: inline;"> · </td><td style="width:1pt;"></td><td align="left" valign="top"> AxoGen pays royalty fees ranging from 1% to 3% under the License Agreements based on net sales of licensed products. One of the agreements also contains a minimum royalty of $12,500 per quarter, which may include a credit in future quarters in the same calendar year for the amount the minimum royalty exceeds the royalty fees. Also, when AxoGen pays royalties to more than one licensor for sales of the same product, a royalty stack cap applies, capping total royalties at 3.75%; </td></tr></table></div>   <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"></td><td valign="top" align="left" style="width: 17.00pt; display: inline;"> · </td><td style="width:1pt;"></td><td align="left" valign="top"> If AxoGen sublicenses technologies covered by the License Agreements to third parties, AxoGen would pay a percentage of sublicense fees received from the third party to the licensor. Currently, AxoGen does not sublicense any technologies covered by License Agreements. The Company is not considered a sub-licensee under the License Agreements and does not owe any sublicensee fees for its own use of the technologies; </td></tr></table></div>   <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"></td><td valign="top" align="left" style="width: 17.00pt; display: inline;"> · </td><td style="width:1pt;"></td><td align="left" valign="top"> AxoGen reimburses the licensors for certain legal expenses incurred for patent prosecution and defense of the technologies covered by the License Agreements; and </td></tr></table></div>   <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"></td><td valign="top" align="left" style="width: 17.00pt; display: inline;"> · </td><td style="width:1pt;"></td><td align="left" valign="top"> Currently, under the University of Texas at Austin’s agreement, AxoGen would owe a $15,000 milestone fee upon receiving a Phase II Small Business Innovation Research or Phase II Small Business Technology Transfer grant involving the licensed technology. The Company has not received either grant and does not owe such a milestone fee.  A Milestone fee to the University of Florida Research Foundation of $2,000 is due if AxoGen receives FDA approval of its Avance® Nerve Graft, $25,000 upon first commercial use of certain licensed technology to provide services to manufacture products for third parties and $10,000 upon first use to manufacture products that utilize certain technology that is not currently incorporated into AxoGen products.</td></tr></table></div>   Royalty fees were approximately $217,000 and $121,000 during the three months ended June 30, 2016 and 2015, respectively, and approximately $370,000 and $217,000 for the six months ended June 30, 2016 and 2015, respectively, and are included in sales and marketing expense on the accompanying condensed consolidated statements of operations. </div><div style="margin-left:0%;margin-right:0%;"> </div><div style="margin-left:0%;margin-right:0%;"></div> </div>

2018522

1023774

2166440

1163413

1649881

1964256

2732823

3243883

3933960

4786322

<div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> Inventories   Inventories are comprised of implantable tissue, nerve grafts, Avance® Nerve Graft, AxoGuard® Nerve Connector, AxoGuard® Nerve Protector, and supplies that are valued at the lower of cost (first-in, first-out) or market and consist of the following:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:74.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30, </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31, </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> </tr> <tr> <td valign="bottom" style="width:74.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Finished goods </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,243,883 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,732,823 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Work in process </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>187,177 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>237,108 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Raw materials </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,355,262 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>964,029 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,786,322 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,933,960 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   Inventories were net of reserve of approximately $820,000 and $711,000 at June 30, 2016 and December 31, 2015, respectively. </div><div style="margin-left:0%;margin-right:0%;"> </div><div style="margin-left:0%;margin-right:0%;"></div> </div>

964029

1355262

711000

820000

237108

187177

28504735

28957634

36700326

31750737

3709245

3922427

416000

24701693

24952201

<div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> 7.    Term Loan Agreement   Term Loan Agreement consists of the following:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:72.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30, </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31, </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> </tr> <tr> <td valign="bottom" style="width:72.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Term Loan and Revenue Interest Agreement with Three Peaks Capital S.a.r.l. for a total term loan amount of $25,000,000 which has a six year term and requires interest only payments and a final principal payment due at the end of the term. Interest is payable quarterly at 9.00% per annum plus the greater of LIBOR or 1.0% which as of June 30, 2016 and December 31, 2015 resulted in a 10% rate. The Revenue Interest Agreement is for a period of ten years. Royalty payments are based on a royalty rate of 3.75% of revenues up to a maximum of $30 million in revenues in any 12 month period. </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>24,952,201 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>24,701,693 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Long-term portion </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.46%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>24,952,201 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.46%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>24,701,693 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   In the first quarter of 2016, the Company adopted ASU 2015-03, “Simplifying the Presentation of Debt Issuance Costs.”  ASU 2015-03 requires debt issuance costs related to recognized debt liabilities to be presented in the balance sheet as a direct deduction from the debt liability rather than an asset.  Accordingly, as of June 30, 2016, approximately $782,000 of deferred debt issuance costs were presented as a direct deduction within Long-Term Debt on the Company’s Condensed Consolidated Balance Sheets.  Furthermore, the Company reclassified approximately $846,000 of deferred debt issuance costs from Other Assets – Deferred Financing Costs to Long-Term Debt as of December 31, 2015.   Term Loan Agreement and Revenue Interest Agreement   On November 12, 2014 (the “Signing Date”), AxoGen, as borrower, and AC, as guarantor, entered into a term loan agreement (the “Term Loan Agreement”) with the lenders party thereto and Three Peaks Capital S.a.r.l. (“Three Peaks”), an indirect wholly-owned subsidiary of Oberland Capital Healthcare Master Fund LP (“Oberland”), as administrative and collateral agent for the lenders thereto. Under the Term Loan Agreement, Three Peaks has agreed to lend to AxoGen a term loan of $25 million (the “Initial Term Loan”) which has a six year term and requires interest only payments and a final principal payment due at the end of the term. Interest is payable quarterly at 9.00% per annum plus the greater of LIBOR or 1.0% which as of November 13, 2014 (“the Initial Closing Date”) resulted in a 10% interest rate.  Under certain conditions, as provided in the Term Loan Agreement, as amended by Amendment 1 to the Term Loan Agreement, dated June 29, 2016, by and among the parties to the Loan Agreement (the “Term Loan Agreement Amendment”), AxoGen has the option to draw an additional $7 million (the “Subsequent Borrowing” and, together with the Initial Term Loan, the “Term Loan”) during the period of July 1, 2016 through September 30, 2016 (the closing date of each such Subsequent Borrowing, a “Subsequent Closing Date” and, together with the Initial Closing Date, the “Closing Dates”) under similar terms and conditions. AxoGen has to comply with certain covenants including limiting new indebtedness, restricting the payment of dividends and maintaining certain levels of revenue. Three Peaks has a first perfected security interest in the assets of AxoGen.   In addition, AxoGen entered into a 10 year Revenue Interest Agreement (the “Revenue Interest Agreement”) with Three Peaks. Royalty payments are based on a royalty rate of 3.75% of AxoGen’s revenues up to a maximum of $30 million in revenues in any 12 month period. In the event the Subsequent Borrowing is drawn, the royalty rate increases proportionally up to a maximum of 4.80%   AxoGen has to comply with certain covenants including those covenants under the Term Loan.   Under the Term Loan Agreement, AxoGen has the option at any time to prepay the Term Loan, in whole or in part, and the Royalty Interest Agreement, defined below, by making the following payment, and Three Peaks has the right to demand the following payment upon a change of control of AxoGen, sale of a majority of AxoGen’s assets or a material adverse change to AxoGen: (i) on or prior to the first anniversary of the applicable Closing Date, 120% of the outstanding principal amount of the Term Loan or any portion being prepaid; (ii) after the first anniversary but no later than the second anniversary of the applicable Closing Date, 135% of the outstanding principal amount of the Term Loan or any portion being prepaid; (iii) after the second anniversary but no later than the third anniversary of the applicable Closing Date, 150% of the outstanding principal amount of the Term Loan or any portion being prepaid; or (iv) after the third anniversary of the applicable Closing Date, an amount generating an internal rate of return of 16.25% of the outstanding principal amount of the Term Loan or any portion being prepaid. In all cases, the amount due is reduced by the sum of interest and principal previously paid and all amounts received under the Revenue Interest Agreement. In each such case AxoGen will also owe an additional 3% of the originally advanced Term Loan amount. Upon payment to Three Peaks, AxoGen would have no further obligations to Three Peaks under the Term Loan or the Revenue Interest Agreement.   In connection with the Term Loan Agreement, on the Signing Date, the Company and AC, its wholly owned subsidiary, entered into a Security Agreement (the “Security Agreement”) with Three Peaks, pursuant to which each of the Company and AC grants to Three Peaks a security interest in certain collateral as specified in the Security Agreement to guarantee the payment in full when due of the secured obligations.  In the event of default per the terms of the Term Loan Agreement, Three Peaks would have the ability to foreclose on the pledged collateral and the Company and AC would not be able to continue its current business if such foreclosure occurred.     Also in connection with the above transaction, the Company sold 1,375,969 shares of its common stock to Three Peaks for a total of $3.55 million (“Three Peaks Equity Sale”) at a price of $2.58 per share.  Pursuant to the equity purchase provisions in the Three Peaks Term Loan Agreement, in the event that, prior to November 12, 2016, we sell our securities at a lower price per share than the $2.58 per share paid by Three Peaks, or where the terms of such subsequent sale are otherwise more favorable, then in such case we have agreed to match the more favorable terms of such subsequent sale with respect to the shares purchased by Three Peaks. A subsequent sale does not include the issuance of securities or options to our employees, officers, directors or consultants pursuant to our approved employee option pool or any other employee stock purchase or option plan existing as of November 12, 2014.   The Company records interest using its best estimate of the effective interest rate.  This estimate takes into account both the rate on the Term Loan Agreement and the rate associated with the 10 year Revenue Interest Agreement with Three Peaks.  The effective interest rate is based on actual payments to date, projected future revenues and the projected royalty payments and the quarterly interest payments due on the Term Loan Agreement.  From time to time, AxoGen will reevaluate the expected cash flows and may adjust the effective interest rate.  Determining the effective interest rate requires judgment and is based on significant assumptions related to estimates of the amounts and timing of future revenue streams.  Determination of these assumptions is highly subjective and different assumptions could lead to materially different outcomes. </div><div style="margin-left:0%;margin-right:0%;"> </div><div style="margin-left:0%;margin-right:0%;"></div> </div>

24701693

24952201

13604663

323510

-186567

-554251

-6010955

-7405556

-6766073

-3190873

-6478787

-2802696

-2069100

-1037604

-2250013

-1196726

-4696973

-2153269

-4228774

-1605970

123000

139000

135000

131000

127000

15183

358221

14378

17380

-20067

-617

340870

187002

180142

54075

97341

132492

456910

424925

615511

13770734

14071

323510

300000

<div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> 4.    Property and Equipment   Property and equipment consist of the following:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:72.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30, </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31, </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> </tr> <tr> <td valign="bottom" style="width:72.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.12%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Furniture and equipment </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,119,698 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,186,815 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Leasehold improvements </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>490,214 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>346,642 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Processing equipment </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,756,214 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,375,759 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Less: accumulated depreciation and amortization </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,105,936) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,938,346) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.12%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.12%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Property and equipment </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,260,190 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>970,870 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   </div><div style="margin-left:0%;margin-right:0%;"> </div><div style="margin-left:0%;margin-right:0%;"></div> </div>

1186815

1375759

346642

1119698

1756214

490214

970870

1260190

<div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:72.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30, </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31, </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> </tr> <tr> <td valign="bottom" style="width:72.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.12%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Furniture and equipment </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,119,698 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,186,815 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Leasehold improvements </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>490,214 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>346,642 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Processing equipment </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,756,214 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,375,759 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Less: accumulated depreciation and amortization </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,105,936) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,938,346) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.12%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.12%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Property and equipment </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,260,190 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>970,870 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   </div><div style="margin-left:0%;margin-right:0%;"> </div><div style="margin-left:0%;margin-right:0%;"></div> </div>

48600

1407435

736399

1915163

936823

-103472679

-109951466

11368569

6417253

18493642

10381883

217000

121000

370000

217000

30000000

<div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:74.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30, </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31, </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> </tr> <tr> <td valign="bottom" style="width:74.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Accounts payable </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.42%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,863,349 </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.42%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,090,874 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Miscellaneous accruals </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>358,221 </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15,183 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Accrued compensation </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,672,264 </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,589,070 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Accounts Payable and Accrued Expenses </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.42%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,893,834 </td> <td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.42%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,695,127 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   </div><div style="margin-left:0%;margin-right:0%;"> </div><div style="margin-left:0%;margin-right:0%;"></div> </div>

<div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:75.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:75.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30, </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31, </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> </tr> <tr> <td valign="bottom" style="width:75.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:75.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.58%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:75.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> License agreements </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>907,545 </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>897,594 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:75.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Patents </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>267,387 </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>179,997 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:75.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Less: accumulated amortization </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(431,542) </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(399,509) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:75.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Intangible assets, net </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.58%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>743,390 </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.14%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.58%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>678,082 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   </div><div style="margin-left:0%;margin-right:0%;"> </div><div style="margin-left:0%;margin-right:0%;"></div> </div>

<div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:74.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30, </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31, </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> </tr> <tr> <td valign="bottom" style="width:74.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Finished goods </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,243,883 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,732,823 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Work in process </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>187,177 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>237,108 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Raw materials </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,355,262 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>964,029 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,786,322 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,933,960 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   </div><div style="margin-left:0%;margin-right:0%;"> </div><div style="margin-left:0%;margin-right:0%;"></div> </div>

8744783

4812262

12986238

6780363

696625

752789

328376

752789

696625

272240

569834

P4Y

0.7624

0.6185

0.0121

0.0123

739000

505750

<div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> Share-Based Compensation   Stock-based compensation cost related to stock options granted under the AC 2002 Stock Option Plan and AxoGen 2010 Stock Incentive Plan (see Note 8) is measured at grant date, based on the fair value of the award, and is recognized as an expense over the employee’s requisite service period. The Company estimates the fair value of each option award issued under the Plan on the date of grant using a Black-Scholes-Merton option-pricing model that uses the assumptions noted in the table below. The Company estimates the volatility of its common stock at the date of grant based on the volatility of comparable peer companies which are publicly traded, for the periods prior to there being a market for the Company’s  common stock, and based on the Company’s common stock for periods subsequent to having an established market for the stock. The Company determines the expected life based on historical experience with similar awards, giving consideration to the contractual terms, vesting schedules and post-vesting forfeitures. The Company uses the risk-free interest rate on the implied yield currently available on U.S. Treasury issues with an equivalent remaining term approximately equal to the expected life of the award. The Company has never paid any cash dividends on its common stock and does not anticipate paying any cash dividends in the foreseeable future. The Company used the following weighted-average assumptions for options granted during the six months ended June 30:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:76.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:03.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:76.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Six months ended June 30, </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:08.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:03.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> </tr> <tr> <td valign="bottom" style="width:76.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:76.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Expected term (in years) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4 </td> <td valign="bottom" style="width:03.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4 </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:76.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Expected volatility </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>61.85 </td> <td valign="bottom" style="width:03.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> %   </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>76.24 </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> % </td> </tr> <tr> <td valign="bottom" style="width:76.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Risk free rate </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.23 </td> <td valign="bottom" style="width:03.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> %   </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.21 </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> % </td> </tr> <tr> <td valign="bottom" style="width:76.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Expected dividends </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:03.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> %   </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> % </td> </tr> </table></div>   The Company estimates forfeitures when recognizing compensation expense and this estimate of forfeitures is adjusted over the requisite service period based on the extent to which actual forfeitures differ, or are expected to differ, from such estimates. Changes in estimated forfeitures are recognized through a cumulative catch-up adjustment, which is recognized in the period of change, and also impact the amount of unamortized compensation expense to be recognized in future periods. The Company did not apply a forfeiture allocation to its unvested options outstanding during the six months ended June 30, 2016 and 2015 as they were deemed insignificant. </div><div style="margin-left:0%;margin-right:0%;"> </div><div style="margin-left:0%;margin-right:0%;"></div> </div>

2.58

2.75

3.60

<div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> 3.    Summary of Significant Accounting Policies   Revenue Recognition   Revenue is recognized when persuasive evidence of an arrangement exists, the price is fixed and determinable, delivery has occurred and there is a reasonable assurance of collection of the sales proceeds. Revenues for manufactured products and products sold to a customer or under a distribution agreement are recognized when the product is shipped to the customer or distributor, at which time title passes to the customer or distributor.  Once a product is shipped, the Company has no further performance obligations. Shipped product is defined as shipment to a customer location or segregation of product into a contracted distribution location. At such time, this product cannot be sold to any other customer. Fees charged to customers for shipping are recognized as revenues when products are shipped to the customer, distributor or end user.  In the case of revenues from consigned sales, revenue is determined when the product is utilized in a surgical procedure. Revenues from research grants are recognized in the period the associated costs are incurred.   Cash and Cash Equivalents and Concentration   For purposes of the statement of cash flows, the Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents. Cash and cash equivalents are maintained at financial institutions and, at times, balances may exceed federally insured limits. The Company has never experienced any losses related to these balances and does not believe it is exposed to any significant credit risk on cash and cash equivalents.   Accounts Receivable and Concentration of Credit Risk   Accounts receivable are carried at the original invoice amount less an estimate made for doubtful accounts based on a review of all outstanding amounts on a monthly basis. Management determines the allowance for doubtful accounts by regularly evaluating individual customer receivables and considering a customer’s financial condition, credit history and current economic conditions. Accounts receivable are written off when deemed uncollectible. Recoveries of accounts receivable previously written off are recorded when received.   We regularly review all accounts that exceed 60 days from the invoice date and based on an assessment of current credit worthiness, estimate the portion, if any, of the balance that will not be collected.  The analysis excludes certain government related receivables due to our past successful experience in collectability.  Specific accounts that are deemed uncollectible are reserved at 100% of their outstanding balance.  The remaining balances outstanding over 60 days have a percentage applied by aging category (5% for balances 61-90 days and 20% for balances over 90 days aged), based on a historical valuation that allows us to calculate the total reserve required.  The reserve balance was determined by applying a percentage to the cumulative balance between 60 and 90 days and a higher percentage to the balance over 90 days.  In the event that we exhaust all collection efforts and deem an account uncollectible, we would subsequently write off the account.  The write off process involves approval by senior management based on the write off amount.  The allowance for doubtful accounts reserve balance was approximately $241,000 and $192,000 at June 30, 2016 and December 31, 2015, respectively.   Concentrations of credit risk with respect to accounts receivable are limited because a large number of geographically diverse customers make up the Company’s customer base, thus spreading the trade credit risk. The Company also controls credit risk through credit approvals, credit limits and monitoring procedures.   Inventories   Inventories are comprised of implantable tissue, nerve grafts, Avance® Nerve Graft, AxoGuard® Nerve Connector, AxoGuard® Nerve Protector, and supplies that are valued at the lower of cost (first-in, first-out) or market and consist of the following:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:74.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30, </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31, </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> </tr> <tr> <td valign="bottom" style="width:74.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Finished goods </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,243,883 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,732,823 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Work in process </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>187,177 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>237,108 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Raw materials </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,355,262 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>964,029 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,786,322 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,933,960 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   Inventories were net of reserve of approximately $820,000 and $711,000 at June 30, 2016 and December 31, 2015, respectively.   Income Taxes   The Company has not recorded current income tax expense due to the generation of net operating losses. Deferred income taxes are accounted for using the balance sheet approach which requires recognition of deferred tax assets and liabilities for the expected future consequences of temporary differences between the financial reporting basis and the tax basis of assets and liabilities. A valuation allowance is provided when it is more likely than not that a deferred tax asset will not be realized. A full valuation allowance has been established on the deferred tax asset as it is more likely than not that a future tax benefit will not be realized. In addition, future utilization of the available net operating loss carryforward may be limited under Internal Revenue Code Section 382 as a result of changes in ownership.   The Company identifies and evaluates uncertain tax positions, if any, and recognizes the impact of uncertain tax positions for which there is a less than more-likely-than-not probability of the position being upheld when reviewed by the relevant taxing authority. Such positions are deemed to be unrecognized tax benefits and a corresponding liability is established on the balance sheet. The Company has not recognized a liability for uncertain tax positions. If there were an unrecognized tax benefit, the Company would recognize interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses. The Company’s remaining open tax years subject to examination by the Internal Revenue Service include the years ended December 31, 2012 through 2015; there currently are no examinations in process.   Fair Value of Financial Instruments   The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include cash, accounts receivable, accounts payable and accrued expenses. The fair value of the Company’s long-term debt approximates its carrying value based upon current rates available to the Company.    Share-Based Compensation   Stock-based compensation cost related to stock options granted under the AC 2002 Stock Option Plan and AxoGen 2010 Stock Incentive Plan (see Note 8) is measured at grant date, based on the fair value of the award, and is recognized as an expense over the employee’s requisite service period. The Company estimates the fair value of each option award issued under the Plan on the date of grant using a Black-Scholes-Merton option-pricing model that uses the assumptions noted in the table below. The Company estimates the volatility of its common stock at the date of grant based on the volatility of comparable peer companies which are publicly traded, for the periods prior to there being a market for the Company’s  common stock, and based on the Company’s common stock for periods subsequent to having an established market for the stock. The Company determines the expected life based on historical experience with similar awards, giving consideration to the contractual terms, vesting schedules and post-vesting forfeitures. The Company uses the risk-free interest rate on the implied yield currently available on U.S. Treasury issues with an equivalent remaining term approximately equal to the expected life of the award. The Company has never paid any cash dividends on its common stock and does not anticipate paying any cash dividends in the foreseeable future. The Company used the following weighted-average assumptions for options granted during the six months ended June 30:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:76.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:03.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:76.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Six months ended June 30, </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:08.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:03.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> </tr> <tr> <td valign="bottom" style="width:76.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:76.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Expected term (in years) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4 </td> <td valign="bottom" style="width:03.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4 </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:76.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Expected volatility </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>61.85 </td> <td valign="bottom" style="width:03.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> %   </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>76.24 </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> % </td> </tr> <tr> <td valign="bottom" style="width:76.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Risk free rate </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.23 </td> <td valign="bottom" style="width:03.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> %   </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.21 </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> % </td> </tr> <tr> <td valign="bottom" style="width:76.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Expected dividends </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:03.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> %   </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> % </td> </tr> </table></div>   The Company estimates forfeitures when recognizing compensation expense and this estimate of forfeitures is adjusted over the requisite service period based on the extent to which actual forfeitures differ, or are expected to differ, from such estimates. Changes in estimated forfeitures are recognized through a cumulative catch-up adjustment, which is recognized in the period of change, and also impact the amount of unamortized compensation expense to be recognized in future periods. The Company did not apply a forfeiture allocation to its unvested options outstanding during the six months ended June 30, 2016 and 2015 as they were deemed insignificant.   Use of Estimates   The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.   Recent Accounting Pronouncements   In May 2014, the Financial Accounting Standards Board, or FASB issued a new standard on revenue recognition which outlines a single comprehensive model to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The core principle of the revenue model is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The standard is designed to create greater comparability for financial statement users across industries and jurisdictions and also requires enhanced disclosures. The guidance was scheduled to become effective for fiscal years, and interim periods within those years, beginning after December 15, 2016; however, on July 9, 2015, the FASB decided to delay the effective date of the new revenue standard by one year.  The proposed deferral may permit early adoption, but would not allow adoption any earlier than the original effective date of the standard. We are currently evaluating the impact this standard will have on our consolidated financial statements.   In June 2014, the FASB issued updated guidance related to stock compensation. The amendment requires that a performance target that affects vesting and that could be achieved after the requisite period, be treated as a performance condition. The updated guidance became effective for annual reporting periods and interim periods within those annual periods beginning after December 15, 2015. The Company has one such stock option grant that is based on quarterly performance conditions and the vesting and compensation expense is measured subsequent to the end of each quarter over a two year period.  If the performance condition is met the vesting and compensation expense is recognized on the measurement date.    In April 2015, the FASB issued Accounting Standard Update (“ASU”) No. 2015-03, "Simplifying the Presentation of Debt Issuance Costs" ("ASU 2015-03") which changes the presentation of debt issuance costs in financial statements to present such costs as a direct deduction from the related debt liability rather than as an asset. ASU 2015-03 became effective for public companies during interim and annual reporting periods beginning after December 15, 2015. Early adoption is permitted. The Company adopted this standard in the first quarter of 2016 on a retrospective basis.  (See note 7)   In November 2015, the FASB issued an ASU to simplify the presentation of deferred income taxes. The amendments in this ASU require that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. The amendments in these ASU may be applied either prospectively to all deferred tax liabilities and assets or retrospectively to all periods presented and are effective for interim and annual reporting periods beginning after December 15, 2016. Earlier application is permitted for all entities as of the beginning of an interim or annual reporting period. We are currently evaluating the impact this standard will have on our consolidated financial statements.   In January 2016, the FASB, issued ASU 2016-01 “Recognition and Measurement of Financial Assets and Financial Liabilities,” which requires that most equity instruments be measured at fair value, with subsequent changes in fair value recognized in net income. The pronouncement also impacts the financial liabilities under the fair value option and the presentation and disclosure requirements for financial instruments. The ASU does not apply to equity method investments or investments in consolidated subsidiaries. The new standard will be effective for us for the year ending December 31, 2018, with early adoption permitted and amendments to be applied as a cumulative-effect adjustment to the balance sheet in the year of adoption. We are currently evaluating the impact this standard will have on our consolidated financial statements.   In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842)”. This update will increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. This update is effective for annual and interim reporting periods beginning after December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted. We are currently evaluating the impact this standard will have on our consolidated financial statements.   In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718), Improvements to Employee Share-Based Payment Accounting. The ASU was issued as part of the FASB Simplification Initiative and involves several aspects of accounting for shared-based payment transactions, including the income tax consequences, options to elect forfeiture accounting policy either by the number of awards that are expected to vest (current GAAP) or account for forfeitures when they occur, and classification on the statement of cash flows. The guidance is effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Early adoption is permitted for any entity in any interim or annual period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. An entity that elects early adoption must adopt all of the amendments in the same period. We are currently evaluating the impact this standard will have on our consolidated financial statements.   The Company’s management has reviewed and considered all other recent accounting pronouncements and we believe there are none that could potentially have a material impact on the Company’s consolidated financial condition, results of operations, or disclosures. </div><div style="margin-left:0%;margin-right:0%;"> </div><div style="margin-left:0%;margin-right:0%;"></div> </div>

8195591

2793103

<div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> 9.   Public Offering of Common Stock   On February 5, 2015, AxoGen entered into an underwriting agreement with Wedbush Securities Inc. (the “Underwriter”) in connection with the offering, issuance and sale (the “February 2015 Offering”) of 4,728,000 shares of the Company’s common stock, at a price to the public of $2.75 per share.  The Company also granted to the Underwriter a 30-day option to purchase up to an aggregate of 709,200 additional shares of the Company’s common stock to cover over-allotments, if any.   As of February 13, 2015, the February 2015 Offering was completed with the sale of 5,437,200 shares of the Company’s common stock, which included the full exercise of the over-allotment option, at $2.75 per share, resulting in gross proceeds to AxoGen from the February 2015 Offering of approximately $15.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by AxoGen estimated at approximately $1.4 million. The shares of Company common stock were listed on the NASDAQ Capital Market.  The February 2015 Offering was made pursuant to the Company’s effective shelf registration statement on Form S-3 (Registration No. 333-195588) previously filed with the SEC on April 30, 2014, and pursuant to the prospectus supplement and the accompanying prospectus describing the terms of the February 2015 Offering, dated February 5, 2015.   On August 26, 2015, the Company entered into the Purchase Agreement with Essex Woodlands Fund IX, L.P. for the purchase of 4,861,111 shares of the Company’s common stock at a public offering price of $3.60 per share, raising approximately $17.5 million in gross proceeds (the “August 2015 Offering”).  The expenses directly related to the August 2015 Offering were approximately $300,000 and were all paid as of December 31, 2015 by the Company.  Such expenses include the Company’s legal and accounting fees, printing expenses, transfer agent fees and miscellaneous fees and costs related to the August 2015 Offering.  Proceeds from the August 2015 Offering will be used for sales and marketing and general working capital purposes. The Company has provided certain demand and “piggy-back” registration rights in connection with this sale of its common stock. The August 2015 Offering was made pursuant to the Company’s effective shelf registration statement on Form S-3 (Registration No. 333-195588) previously filed with the SEC on April 30, 2014 and pursuant to the prospectus supplement and the accompanying prospectus describing the terms of the August 2015 Offering, dated August 26, 2015.   The August 2015 Offering was made pursuant to the Company’s effective shelf registration statement on Form S-3 (Registration No. 333-195588) previously filed with the SEC on April 30, 2014, and pursuant to the prospectus supplement and the accompanying prospectus describing the terms of the Offering, dated August 26, 2015. </div><div style="margin-left:0%;margin-right:0%;"> </div><div style="margin-left:0%;margin-right:0%;"></div> </div>

23729558

24928435

30037013

30079960

EX-101.SCH 6 axgn-20160630.xsd EX-101.SCH 00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 40302 - Disclosure - Summary of Significant Accounting Policies - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 40401 - Disclosure - Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - Intangible Assets - Components of Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 40601 - Disclosure - Accounts Payable and Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00105 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 10101 - Disclosure - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 10201 - Disclosure - Organization and Business link:presentationLink link:calculationLink link:definitionLink 10301 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 10401 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 10501 - Disclosure - Intangible Assets link:presentationLink link:calculationLink link:definitionLink 10601 - Disclosure - Accounts Payable and Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 10701 - Disclosure - Term Loan Agreement link:presentationLink link:calculationLink link:definitionLink 10801 - Disclosure - Stock Options link:presentationLink link:calculationLink link:definitionLink 10901 - Disclosure - Public Offering of Common Stock link:presentationLink link:calculationLink link:definitionLink 11001 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 11101 - Disclosure - Retirement Plan link:presentationLink link:calculationLink link:definitionLink 20302 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 30303 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 30403 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 30503 - Disclosure - Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 30603 - Disclosure - Accounts Payable and Accrued Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 30703 - Disclosure - Term Loan Agreement (Tables) link:presentationLink link:calculationLink link:definitionLink 40301 - Disclosure - Summary of Significant Accounting Policies - Accounts Receivable and Concentration of Credit Risk (Details) link:presentationLink link:calculationLink link:definitionLink 40303 - Disclosure - Summary of Significant Accounting Policies - Stock-Based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 40502 - Disclosure - Intangible Assets - Future Amortization Expense (Details) link:presentationLink link:calculationLink link:definitionLink 40503 - Disclosure - Intangible Assets - License Agreements (Details) link:presentationLink link:calculationLink link:definitionLink 40701 - Disclosure - Term Loan Agreement - Long-term Portion (Details) link:presentationLink link:calculationLink link:definitionLink 40702 - Disclosure - Note Payable and Term Loan Agreement - Term Loan Agreement and Revenue Interest Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 40801 - Disclosure - Stock Options (Details) link:presentationLink link:calculationLink link:definitionLink 40901 - Disclosure - Public Offering of Common Stock (Details) link:presentationLink link:calculationLink link:definitionLink 41001 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 41101 - Disclosure - Retirement Plan (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 axgn-20160630_cal.xml EX-101.CAL EX-101.DEF 8 axgn-20160630_def.xml EX-101.DEF EX-101.LAB 9 axgn-20160630_lab.xml EX-101.LAB Document and Entity Information Statement [Table] Statement [Line Items] Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Current Reporting Status Entity Filer Category Entity Common Stock, Shares Outstanding Document Fiscal Year Focus Document Fiscal Period Focus Condensed Consolidated Balance Sheets Assets [Abstract] Assets Assets, Current [Abstract] Current assets: Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents, end of period Cash and cash equivalents, beginning of year Cash and cash equivalents Accounts receivable, net of allowance for doubtful accounts of approximately $54,000 and $59,000, respectively Accounts receivable, net of allowance for doubtful accounts of approximately $241,000 and $192,000 respectively Inventory, Net Inventory Inventory, Net Prepaid Expense and Other Assets, Current Prepaid expenses and other Assets, Current Total current assets Property, Plant and Equipment, Net Property and equipment, net Property and equipment Finite-Lived Intangible Assets, Net Intangible assets Intangible assets, net Assets Total Assets Liabilities and Equity [Abstract] Liabilities and Shareholders' Equity Liabilities, Current [Abstract] Current liabilities: Accounts Payable and Accrued Liabilities, Current Accounts payable and accrued expenses Accounts Payable and Accrued Expenses Deferred Revenue, Current Current deferred revenue Liabilities, Current Total current liabilities Notes Payable, Noncurrent Total Debt Note Payable - Revenue Interest Purchase Agreement Deferred Revenue, Noncurrent Long Term Deferred Revenue Liabilities Total liabilities Stockholders' Equity Attributable to Parent [Abstract] Shareholders' equity: Common Stock, Value, Issued Common stock, $0.01 par value per share; 50,000,000 shares authorized; 30,128,099 and 29,984,591 shares issued and outstanding Value of common stock sold Additional Paid in Capital, Common Stock Additional paid-in capital Retained Earnings (Accumulated Deficit) Accumulated deficit Stockholders' Equity Attributable to Parent Total shareholders' equity (deficit) Liabilities and Equity Total Liabilities and Shareholders' equity Allowance for Doubtful Accounts Receivable, Current Accounts receivable, allowance for doubtful accounts Allowance for doubtful accounts reserve balance Common Stock, Par or Stated Value Per Share Common stock, Par value Par value of common stock Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Shares of common stock sold Common Stock, Shares, Outstanding Common stock, shares outstanding Condensed Consolidated Statements of Operations Revenues Revenues Cost of Goods Sold Cost of goods sold Gross Profit Gross profit Costs and Expenses [Abstract] Costs and expenses: Selling and Marketing Expense. Sales and marketing Research and Development Expense Research and development General and Administrative Expense General and administrative Costs and Expenses Total costs and expenses Operating Income (Loss) Loss from operations Nonoperating Income (Expense) [Abstract] Other income (expense): Interest Expense Interest expense Amortization of Financing Costs and Discounts Interest expense-deferred financing costs Other Nonoperating Income (Expense) Other income (expense) Nonoperating Income (Expense) Total other income (expense) Net Loss Net loss Net Loss Weighted Average Number of Shares Outstanding, Basic and Diluted Weighted Average Common Shares outstanding - basic and diluted Earnings Per Share, Basic and Diluted Loss Per Common share - basic and diluted (in dollars per share) Condensed Consolidated Statements of Cash Flows Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Cash flows from operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used for operating activities: Depreciation Amortization of Intangible Assets Amortization of intangible assets Amortization of deferred financing costs Amortization of deferred financing costs Provision for Doubtful Accounts Provision for bad debt Share-based Compensation Stock-based compensation Paid-in-Kind Interest Interest added to note payable Increase (Decrease) in Operating Capital [Abstract] Change in assets and liabilities: Increase (Decrease) in Accounts Receivable Accounts receivable Increase (Decrease) in Inventories Inventory Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other Increase (Decrease) in Accounts Payable and Accrued Liabilities Accounts payable and accrued expenses Increase (Decrease) in Deferred Revenue Deferred revenue Net Cash Provided by (Used in) Operating Activities, Continuing Operations Net cash used for operating activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Cash flows from investing activities: Payments to Acquire Property, Plant, and Equipment Purchase of property and equipment Payments to Acquire Intangible Assets Acquisition of intangible assets Net Cash Provided by (Used in) Investing Activities, Continuing Operations Net cash used for investing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Cash flows from financing activities: Proceeds from Issuance of Common Stock Proceeds from issuance of common stock Payments of Debt Issuance Costs Debt issuance costs Proceeds from Stock Options Exercised Proceeds from exercise of stock options Net Cash Provided by (Used in) Financing Activities, Continuing Operations Net cash provided by (used in) financing activities Cash and Cash Equivalents, Period Increase (Decrease) Net increase / (decrease) in cash and cash equivalents Supplemental Cash Flow Information [Abstract] Supplemental disclosures of cash flow activity: Interest Paid Cash paid for interest Basis of Presentation Basis of Accounting [Text Block] Basis of Presentation Organization and Business Nature of Operations [Text Block] Organization and Business Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Summary of Significant Accounting Policies Property and Equipment Property, Plant and Equipment Disclosure [Text Block] Property and Equipment Intangible Assets Intangible Assets Disclosure [Text Block] Intangible Assets Accounts Payable and Accrued Expenses Accounts Payable and Accrued Liabilities Disclosure [Text Block] Accounts Payable and Accrued Expenses Term Loan Agreement Long-term Debt [Text Block] Term Loan Agreement Stock Options. Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Stock Options Shareholders' Equity (Deficit) and Temporary Equity Stockholders' Equity Note Disclosure [Text Block] Public Offering of Common Stock Commitments and Contingencies. Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Retirement Plan Pension and Other Postretirement Benefits Disclosure [Text Block] Retirement Plan Revenue Recognition, Policy [Policy Text Block] Revenue Recognition Cash and Cash Equivalents, Policy [Policy Text Block] Cash and Cash Equivalents and Concentration Trade and Other Accounts Receivable, Policy [Policy Text Block] Accounts Receivable and Concentration of Credit Risk Inventory, Policy [Policy Text Block] Inventories Income Tax, Policy [Policy Text Block] Income Taxes Fair Value of Financial Instruments, Policy [Policy Text Block] Fair Value of Financial Instruments Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] Share-Based Compensation Use of Estimates, Policy [Policy Text Block] Use of Estimates New Accounting Pronouncements, Policy [Policy Text Block] Recent Accounting Pronouncements Schedule of Inventory, Current [Table Text Block] Schedule of inventories Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of weighted-average assumptions for options granted Property, Plant and Equipment [Table Text Block] Schedule of Property and equipment Schedule of Finite-Lived Intangible Assets [Table Text Block] Schedule of intangible assets Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Schedule of accounts payable and accrued expenses Schedule of Long-term Debt Instruments [Table Text Block] Schedule of Term Loan Agreement Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Financing Receivables, Period Past Due [Axis] Financing Receivables Period Past Due [Domain] Financing Receivables, Period Past Due [Domain] Financing Receivables60 To89 Days Past Due [Member] Age 61 to 90 Days Financing Receivables Equal To Greater Than90 Days Past Due [Member] Age Over 90 Days Range [Axis] Range [Member] Range [Domain] Minimum [Member] Minimum Maximum [Member] Maximum Accounts, Notes, Loans and Financing Receivable [Line Items] Accounts Receivable and Concentration of Credit Risk Represents the reserve for accounts deemed uncollectible, expressed as a percentage. Reserve for Accounts Receivable Deemed Uncollectible Percentage Reserve for accounts deemed uncollectible (as a percent) Represents the age of specific types of trade accounts and notes receivable. Allowance for Doubtful Accounts Receivable Age of Accounts Receivable Age of doubtful accounts Represents the valuation allowance for receivables due, that are expected to be uncollectible, expressed as a percentage. Allowance for Doubtful Accounts Receivable Percentage Reserve for doubtful accounts (as a percent) Inventory, Finished Goods, Net of Reserves Finished goods Inventory, Work in Process, Net of Reserves Work in process Inventory, Raw Materials, Net of Reserves Raw materials Inventory Valuation Reserves Inventory valuation reserves Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Expected term Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Expected volatility (as a percent) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Risk free rate (as a percent) Property, Plant and Equipment [Table] Property, Plant and Equipment, Type [Axis] Property Plant And Equipment Type [Domain] Property, Plant and Equipment, Type [Domain] Equipment and tangible personal property commonly used in offices. Furniture And Office Equipment [Member] Furniture and Office Equipment Leasehold Improvements [Member] Leasehold Improvements Equipment [Member] Processing equipment Property, Plant and Equipment [Line Items] Property and equipment Property, Plant and Equipment, Gross Property and equipment, Gross Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Less: accumulated depreciation and amortization Schedule of Finite-Lived Intangible Assets [Table] Finite-Lived Intangible Assets by Major Class [Axis] Finite Lived Intangible Assets Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Licensing Agreements [Member] Licensing Agreements Patents [Member] Patents Finite-Lived Intangible Assets [Line Items] Intangible assets Intangible assets consist of: Finite-Lived Intangible Assets, Gross Finite-lived intangible assets, gross Finite-Lived Intangible Assets, Accumulated Amortization Less: accumulated amortization Finite-Lived Intangible Assets, Remaining Amortization Period Amortization period of intangible assets Represents capitalized costs related to patents that are pending, not currently subject to amortization. Amount is included in total of finite lived intangible assets gross. Nonamortizable Pending Patent Costs Non-amortizable pending costs Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract] Future amortization of license and patent agreements Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year Remainder of 2016 Finite-Lived Intangible Assets, Amortization Expense, Year Two 2017 Finite-Lived Intangible Assets, Amortization Expense, Year Three 2018 Finite-Lived Intangible Assets, Amortization Expense, Year Four 2019 Finite-Lived Intangible Assets, Amortization Expense, Year Five 2020 Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the sixth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. Finite-Lived Intangible Assets, Amortization Expense, Year Six 2021 Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the seventh fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. Finite-Lived Intangible Assets, Amortization Expense, Year Seven 2022 Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the eighth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. Finite-Lived Intangible Assets, Amortization Expense, Year Eight 2023 Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Selling And Marketing Expense [Member] Sales and Marketing Expense Notice period for termination of license agreements. Notice Period for Termination of License Agreements License agreements extended period Royalty fees percentage under license agreements. Royalty Fees Percentage under License Agreements Royalty fees range under the license agreements Minimum quarterly royalty required under the terms of one of the reporting entity's licensing arrangements. Minimum Royalty of License Agreement Minimum royalty of agreements The maximum percentage of royalty which may be paid for the sale of the same product, pursuant to a capping arrangement in the license agreements. Percentage of Capping Royalties for Multiple Royalty Payments to Licensors Royalty stack cap for royalties paid to more than one licensor for sales of the same product Represents the amount of milestone payment due if the reporting entity receives a grant under one of the grants specified in the license agreement. Milestone Payment Contingent upon Receipt of Grant Milestone fee upon receiving a Phase II Small Business Innovation Research Represents the amount of milestone payment due if AxoGen receives FDA approval of its Avance® Nerve Graft. Milestone Payment Contingent Upon F D A Approval Milestone fee upon FDA approval Represents the amount of milestone payment due upon first commercial use of certain licensed technology to provide services to manufacture products for third parties. Milestone Payment Contingent Upon First Commercial Use of Certain Licensed Technology Milestone fee upon first commercial use of certain licensed technology Represents the amount of milestone payment due upon first use to manufacture products that utilize certain technology that is not currently incorporated into AxoGen products. Milestone Payment Contingent Upon First Use to Manufacture Products Utilizing Certain Technology Milestone fee upon first use to manufacture products that utilize certain technology not currently incorporated into AxoGen products Royalty Expense Royalty fees included in sales and marketing expense Accounts Payable and Accrued Liabilities Accounts Payable, Current Accounts payable Miscellaneous Accruals Current Miscellaneous accruals Accrued Compensation Current Accrued compensation Schedule of Long-term Debt Instruments [Table] Legal Entity [Axis] Entity [Domain] Entity [Domain] EX-101.PRE 10 axgn-20160630_pre.xml EX-101.PRE XML 11 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2016	Aug. 03, 2016
Document and Entity Information
Entity Registrant Name	AxoGen, Inc.
Entity Central Index Key	0000805928
Document Type	10-Q
Document Period End Date	Jun. 30, 2016
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		30,132,224
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	Q2

XML 12 R2.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Jun. 30, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 18,273,203	$ 25,909,500
Accounts receivable, net of allowance for doubtful accounts of approximately $241,000 and $192,000 respectively	6,072,121	4,782,989
Inventory	4,786,322	3,933,960
Prepaid expenses and other	615,511	424,925
Total current assets	29,747,157	35,051,374
Property and equipment, net	1,260,190	970,870
Intangible assets	743,390	678,082
Total Assets	31,750,737	36,700,326
Current liabilities:
Accounts payable and accrued expenses	3,893,834	3,695,127
Current deferred revenue	28,593	14,118
Total current liabilities	3,922,427	3,709,245
Note Payable - Revenue Interest Purchase Agreement	24,952,201	24,701,693
Long Term Deferred Revenue	83,006	93,797
Total liabilities	28,957,634	28,504,735
Shareholders' equity:
Common stock, $0.01 par value per share; 50,000,000 shares authorized; 30,128,099 and 29,984,591 shares issued and outstanding	301,281	299,846
Additional paid-in capital	112,443,288	111,368,424
Accumulated deficit	(109,951,466)	(103,472,679)
Total shareholders' equity (deficit)	2,793,103	8,195,591
Total Liabilities and Shareholders' equity	$ 31,750,737	$ 36,700,326

XML 13 R3.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)	Jun. 30, 2016	Dec. 31, 2015
Condensed Consolidated Balance Sheets
Accounts receivable, allowance for doubtful accounts	$ 241,000	$ 192,000
Common stock, Par value	$ 0.01	$ 0.01
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	30,128,099	29,984,591
Common stock, shares outstanding	30,128,099	29,984,591

XML 14 R4.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Condensed Consolidated Statements of Operations
Revenues	$ 10,381,883	$ 6,417,253	$ 18,493,642	$ 11,368,569
Cost of goods sold	1,534,412	1,039,841	2,940,003	2,022,722
Gross profit	8,847,471	5,377,412	15,553,639	9,345,847
Costs and expenses:
Sales and marketing	6,780,363	4,812,262	12,986,238	8,744,783
Research and development	936,823	736,399	1,915,163	1,407,435
General and administrative	2,736,255	1,982,020	4,881,012	3,890,602
Total costs and expenses	10,453,441	7,530,681	19,782,413	14,042,820
Loss from operations	(1,605,970)	(2,153,269)	(4,228,774)	(4,696,973)
Other income (expense):
Interest expense	(1,163,413)	(1,023,774)	(2,166,440)	(2,018,522)
Interest expense-deferred financing costs	(32,696)	(31,210)	(63,506)	(64,956)
Other income (expense)	(617)	17,380	(20,067)	14,378
Total other income (expense)	(1,196,726)	(1,037,604)	(2,250,013)	(2,069,100)
Net Loss	$ (2,802,696)	$ (3,190,873)	$ (6,478,787)	$ (6,766,073)
Weighted Average Common Shares outstanding - basic and diluted	30,079,960	24,928,435	30,037,013	23,729,558
Loss Per Common share - basic and diluted (in dollars per share)	$ (0.09)	$ (0.13)	$ (0.22)	$ (0.29)

XML 15 R5.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Cash flows from operating activities:
Net loss	$ (6,478,787)	$ (6,766,073)
Adjustments to reconcile net loss to net cash used for operating activities:
Depreciation	167,590	87,610
Amortization of intangible assets	32,033	22,710
Amortization of deferred financing costs	63,506	64,957
Provision for bad debt	48,600
Stock-based compensation	752,789	696,625
Interest added to note payable	187,002	340,870
Change in assets and liabilities:
Accounts receivable	(1,337,732)	(965,715)
Inventory	(852,362)	(326,337)
Prepaid expenses and other	(190,586)	(131,739)
Accounts payable and accrued expenses	198,707	976,928
Deferred revenue	3,684	(10,791)
Net cash used for operating activities	(7,405,556)	(6,010,955)
Cash flows from investing activities:
Purchase of property and equipment	(456,910)	(132,492)
Acquisition of intangible assets	(97,341)	(54,075)
Net cash used for investing activities	(554,251)	(186,567)
Cash flows from financing activities:
Proceeds from issuance of common stock		13,770,734
Debt issuance costs		(180,142)
Proceeds from exercise of stock options	323,510	14,071
Net cash provided by (used in) financing activities	323,510	13,604,663
Net increase / (decrease) in cash and cash equivalents	(7,636,297)	7,407,141
Cash and cash equivalents, beginning of year	25,909,500	8,215,791
Cash and cash equivalents, end of period	18,273,203	15,622,932
Supplemental disclosures of cash flow activity:
Cash paid for interest	$ 1,964,256	$ 1,649,881

XML 16 R6.htm IDEA: XBRL DOCUMENT

Basis of Presentation	6 Months Ended
Basis of Presentation	Jun. 30, 2016
Basis of Presentation
Basis of Presentation	1. Basis of Presentation The accompanying condensed consolidated financial statements include the accounts of AxoGen, Inc. (the “Company” or “AxoGen”) and its wholly owned subsidiary AxoGen Corporation (“AC”) as of June 30, 2016 and December 31, 2015 and for the three and six month periods ended June 30, 2016 and 2015. The Company’s condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and should be read in conjunction with the audited financial statements of the Company for the year ended December 31, 2015, which are included in the Company’s Annual Report on Form 10-K as of and for the year ended December 31, 2015. The interim condensed consolidated financial statements are unaudited and in the opinion of management, reflect all adjustments necessary for a fair presentation of results for the periods presented. Results for interim periods are not necessarily indicative of results for the full year. All significant intercompany accounts and transactions have been eliminated in consolidation.

XML 17 R7.htm IDEA: XBRL DOCUMENT

Organization and Business	6 Months Ended
Organization and Business	Jun. 30, 2016
Organization and Business
Organization and Business	2. Organization and Business Business Summary We are a global leader in innovative surgical solutions for peripheral nerve injuries. Our portfolio of products includes Avance® Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard® Nerve Connector, a porcine submucosa extracellular matrix ("ECM") coaptation aid for tensionless repair of severed nerves, and AxoGuard® Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments. Along with these core surgical products, AxoGen also offers AxoTouchTM Two-Point Discriminator and AcroValTM Neurosensory & Motor Testing System. These evaluation and measurement tools assist healthcare professionals in detecting changes in sensation, assessing return of sensory, grip and pinch function, evaluating effective treatment interventions, and providing feedback to patients on nerve function. The AxoGen portfolio of products is available in the United States, Canada, the United Kingdom and several European and international countries. Avance® Nerve Graft is processed in the United States by AxoGen. AxoGuard® Nerve Connector and AxoGuard® Nerve Protector are manufactured in the United States by Cook Biotech Incorporated and are distributed worldwide exclusively by AxoGen. The AcroVal™ Neurosensory and Motor Testing System and AxoTouch™ Two Point Discriminator are contract manufactured by Viron Technologies, LLC. (formerly Cybernetics Research Laboratories) (“Viron”), Tucson, Arizona. Viron supplies the AcroVal™ and AxoTouch™ unpackaged and they are packaged at AxoGen’s distribution facility in Burleson, Texas. AxoGen maintains its corporate offices in Alachua, Florida and is the parent company of its wholly owned operating subsidiary, AC.

XML 18 R8.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies

6 Months Ended

Jun. 30, 2016

Summary of Significant Accounting Policies

Summary of Significant Accounting Policies

3. Summary of Significant Accounting Policies

Revenue Recognition

Revenue is recognized when persuasive evidence of an arrangement exists, the price is fixed and determinable, delivery has occurred and there is a reasonable assurance of collection of the sales proceeds. Revenues for manufactured products and products sold to a customer or under a distribution agreement are recognized when the product is shipped to the customer or distributor, at which time title passes to the customer or distributor. Once a product is shipped, the Company has no further performance obligations. Shipped product is defined as shipment to a customer location or segregation of product into a contracted distribution location. At such time, this product cannot be sold to any other customer. Fees charged to customers for shipping are recognized as revenues when products are shipped to the customer, distributor or end user. In the case of revenues from consigned sales, revenue is determined when the product is utilized in a surgical procedure. Revenues from research grants are recognized in the period the associated costs are incurred.

Cash and Cash Equivalents and Concentration

Accounts Receivable and Concentration of Credit Risk

Inventories


	June 30,		December 31,
	2016		2015

Finished goods	$	3,243,883	$	2,732,823
Work in process		187,177		237,108
Raw materials		1,355,262		964,029
	$	4,786,322	$	3,933,960

Inventories were net of reserve of approximately $820,000 and $711,000 at June 30, 2016 and December 31, 2015, respectively.

Income Taxes

Fair Value of Financial Instruments

Share-Based Compensation


Six months ended June 30,	2016		2015

Expected term (in years)	4		4
Expected volatility	61.85	%	76.24	%
Risk free rate	1.23	%	1.21	%
Expected dividends	—	%	—	%

Use of Estimates

Recent Accounting Pronouncements

XML 19 R9.htm IDEA: XBRL DOCUMENT

Property and Equipment

6 Months Ended

Jun. 30, 2016

Property and Equipment

Property and Equipment

4. Property and Equipment

Property and equipment consist of the following:


	June 30,		December 31,
	2016		2015

Furniture and equipment	$	1,119,698	$	1,186,815
Leasehold improvements		490,214		346,642
Processing equipment		1,756,214		1,375,759
Less: accumulated depreciation and amortization		(2,105,936)		(1,938,346)

Property and equipment	$	1,260,190	$	970,870

XML 20 R10.htm IDEA: XBRL DOCUMENT

Intangible Assets

6 Months Ended

Jun. 30, 2016

Intangible Assets

Intangible Assets

5. Intangible Assets

The Company’s intangible assets consist of the following:


	June 30,		December 31,
	2016		2015

License agreements	$	907,545	$	897,594
Patents		267,387		179,997
Less: accumulated amortization		(431,542)		(399,509)
Intangible assets, net	$	743,390	$	678,082

License Agreements

AxoGen reimburses the licensors for certain legal expenses incurred for patent prosecution and defense of the technologies covered by the License Agreements; and

XML 21 R11.htm IDEA: XBRL DOCUMENT

Accounts Payable and Accrued Expenses

6 Months Ended

Jun. 30, 2016

Accounts Payable and Accrued Expenses

Accounts Payable and Accrued Expenses

6. Accounts Payable and Accrued Expenses

Accounts payable and accrued expenses consist of the following:


	June 30,		December 31,
	2016		2015
Accounts payable	$	1,863,349	$	2,090,874
Miscellaneous accruals		358,221		15,183
Accrued compensation		1,672,264		1,589,070
Accounts Payable and Accrued Expenses	$	3,893,834	$	3,695,127

XML 22 R12.htm IDEA: XBRL DOCUMENT

Term Loan Agreement

6 Months Ended

Jun. 30, 2016

Term Loan Agreement

Term Loan Agreement

7. Term Loan Agreement

Term Loan Agreement consists of the following:


	June 30,		December 31,
	2016		2015
Term Loan and Revenue Interest Agreement with Three Peaks Capital S.a.r.l. for a total term loan amount of $25,000,000 which has a six year term and requires interest only payments and a final principal payment due at the end of the term. Interest is payable quarterly at 9.00% per annum plus the greater of LIBOR or 1.0% which as of June 30, 2016 and December 31, 2015 resulted in a 10% rate. The Revenue Interest Agreement is for a period of ten years. Royalty payments are based on a royalty rate of 3.75% of revenues up to a maximum of $30 million in revenues in any 12 month period.	$	24,952,201	$	24,701,693
Long-term portion	$	24,952,201	$	24,701,693

Term Loan Agreement and Revenue Interest Agreement

Under the Term Loan Agreement, AxoGen has the option at any time to prepay the Term Loan, in whole or in part, and the Royalty Interest Agreement, defined below, by making the following payment, and Three Peaks has the right to demand the following payment upon a change of control of AxoGen, sale of a majority of AxoGen’s assets or a material adverse change to AxoGen: (i) on or prior to the first anniversary of the applicable Closing Date, 120% of the outstanding principal amount of the Term Loan or any portion being prepaid; (ii) after the first anniversary but no later than the second anniversary of the applicable Closing Date, 135% of the outstanding principal amount of the Term Loan or any portion being prepaid; (iii) after the second anniversary but no later than the third anniversary of the applicable Closing Date, 150% of the outstanding principal amount of the Term Loan or any portion being prepaid; or (iv) after the third anniversary of the applicable Closing Date, an amount generating an internal rate of return of 16.25% of the outstanding principal amount of the Term Loan or any portion being prepaid. In all cases, the amount due is reduced by the sum of interest and principal previously paid and all amounts received under the Revenue Interest Agreement. In each such case AxoGen will also owe an additional 3% of the originally advanced Term Loan amount. Upon payment to Three Peaks, AxoGen would have no further obligations to Three Peaks under the Term Loan or the Revenue Interest Agreement.

XML 23 R13.htm IDEA: XBRL DOCUMENT

Stock Options	6 Months Ended
Stock Options	Jun. 30, 2016
Stock Options.
Stock Options	8. Stock Options The Company granted stock options to purchase 505,750 shares of its common stock pursuant to the AxoGen Plan for the six months ended June 30, 2016. Stock-based compensation expense was $569,834 and $328,376 for the three months ended June 30, 2016 and 2015, respectively and $752,789 and $696,625 for the six months ended June 30, 2016 and 2015, respectively. In the period August 2015 through March 2016, we issued 739,000 stock options to certain officers, directors and employees under the AxoGen 2010 stock option plan. The options were subject to shareholder approval to increase the number of shares authorized under the plan. On May 26, 2016, the shareholder approval was obtained and as a result we recognized stock-based compensation of $272,240 related to these options for the three months ended June 30, 2016. Total future stock compensation expense related to nonvested awards is expected to be approximately $2,959,000 at June 30, 2016.

XML 24 R14.htm IDEA: XBRL DOCUMENT

Public Offering of Common Stock	6 Months Ended
Public Offering of Common Stock	Jun. 30, 2016
Shareholders' Equity (Deficit) and Temporary Equity
Public Offering of Common Stock	9. Public Offering of Common Stock On February 5, 2015, AxoGen entered into an underwriting agreement with Wedbush Securities Inc. (the “Underwriter”) in connection with the offering, issuance and sale (the “February 2015 Offering”) of 4,728,000 shares of the Company’s common stock, at a price to the public of $2.75 per share. The Company also granted to the Underwriter a 30-day option to purchase up to an aggregate of 709,200 additional shares of the Company’s common stock to cover over-allotments, if any. As of February 13, 2015, the February 2015 Offering was completed with the sale of 5,437,200 shares of the Company’s common stock, which included the full exercise of the over-allotment option, at $2.75 per share, resulting in gross proceeds to AxoGen from the February 2015 Offering of approximately $15.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by AxoGen estimated at approximately $1.4 million. The shares of Company common stock were listed on the NASDAQ Capital Market. The February 2015 Offering was made pursuant to the Company’s effective shelf registration statement on Form S-3 (Registration No. 333-195588) previously filed with the SEC on April 30, 2014, and pursuant to the prospectus supplement and the accompanying prospectus describing the terms of the February 2015 Offering, dated February 5, 2015. On August 26, 2015, the Company entered into the Purchase Agreement with Essex Woodlands Fund IX, L.P. for the purchase of 4,861,111 shares of the Company’s common stock at a public offering price of $3.60 per share, raising approximately $17.5 million in gross proceeds (the “August 2015 Offering”). The expenses directly related to the August 2015 Offering were approximately $300,000 and were all paid as of December 31, 2015 by the Company. Such expenses include the Company’s legal and accounting fees, printing expenses, transfer agent fees and miscellaneous fees and costs related to the August 2015 Offering. Proceeds from the August 2015 Offering will be used for sales and marketing and general working capital purposes. The Company has provided certain demand and “piggy-back” registration rights in connection with this sale of its common stock. The August 2015 Offering was made pursuant to the Company’s effective shelf registration statement on Form S-3 (Registration No. 333-195588) previously filed with the SEC on April 30, 2014 and pursuant to the prospectus supplement and the accompanying prospectus describing the terms of the August 2015 Offering, dated August 26, 2015. The August 2015 Offering was made pursuant to the Company’s effective shelf registration statement on Form S-3 (Registration No. 333-195588) previously filed with the SEC on April 30, 2014, and pursuant to the prospectus supplement and the accompanying prospectus describing the terms of the Offering, dated August 26, 2015.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

+ Details

XML 25 R15.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies	6 Months Ended
Commitments and Contingencies	Jun. 30, 2016
Commitments and Contingencies.
Commitments and Contingencies	10. Commitments and Contingencies Commercial Lease On March 16, 2016, AC entered into the Fourth Amendment to Lease (“Fourth Amendment”) with SNH Medical Office Properties Trust, a Maryland real estate investment trust (“SNH”). SNH is the landlord of AC’s currently leased 11,761 square foot corporate headquarters facility in Alachua, Florida (the “Current Premises”) pursuant to that certain lease dated as of February 6, 2007, as amended (the “Lease”). The Fourth Amendment expands the Current Premises by 7,050 square feet (the “Expansion Premises”). The Fourth Amendment also provides that the Expiration Date (as defined in the Fourth Amendment) of the Lease will be extended to approximately five years from the Occupancy Date (as defined in the Fourth Amendment) of the Expansion Premises, which Occupancy Date is occurred in June 2016. The original expiration date of the Current Premises remains unchanged; provided, however, that AC shall have the right to extend the Current Premises Term (as defined in the Fourth Amendment) for three additional periods (the “Current Premises Extended Term”), the first such Current Premises Extended Term to commence on November 1, 2018 and end on October 31, 2019, the second such Current Premises Extended Term to commence on November 1, 2019 and end on October 31, 2020, and the third such Current Premises Extended Term to commence on November 1, 2020 and end on the Expiration Date. AC also has the right to extend the term of the then current Leased Premises (as defined in the Fourth Amendment) for an additional period of five years commencing on the day immediately after the Expiration Date. AC’s additional annual cost of the Expansion Premises will be approximately $123,000, $127,000, $131,000, $135,000 and $139,000 for years one through five, respectively, of the Lease, with year one commencing on the Occupancy Date. Processing Agreement Until February 2016, the Company was party to that certain Amended and Restated Nerve Tissue Processing Agreement (the “LifeNet Agreement”) with LifeNet Health (“LifeNet”), whereby the Company processed and packaged Avance® Nerve Graft using its employees and equipment located at LifeNet in Virginia Beach, Virginia (the “Virginia Beach Facility”). As a result of business requirements of LifeNet and their need for additional space, on April 16, 2015 LifeNet notified the Company that it would need to transition out of the Virginia Beach Facility and the LifeNet Agreement was terminated effective February 27, 2016. As a result of the termination of the LifeNet Agreement, on August 6, 2015 the Company entered into a License and Services Agreement (the “CTS Agreement”) with Community Blood Center (d/b/a Community Tissue Services) (“CTS”) whose headquarters are located in Dayton, Ohio. The CTS facility and CTS Agreement provides the Company a cost effective, quality controlled and licensed facility to process and package its Avance® Nerve Graft using the Company’s employees and processing equipment. The processing that was performed at the Virginia Beach Facility has been transferred in its entirety to the CTS facility. The CTS Agreement is for a five-year term, subject to earlier termination by either party for cause, or after the two-year anniversary of the CTS Agreement without cause, upon 18 months notice. Under the CTS Agreement, the Company pays CTS a facility fee for clean room/processing, storage and office space and CTS provides services in support of the Company’s processing such as routine sterilization of daily supplies, providing disposable supplies, microbial services and office support. The service fee is based on a per donor batch rate. However, AxoGen could reproduce a manufacturing space that would meet its needs if it no longer continued its relationship with CTS. AxoGen’s processing methods and process controls have been developed and validated to ensure product uniformity and quality. Pursuant to the CTS Agreement, AxoGen pays license fees on a monthly basis to CTS which total an annual amount of approximately $416,000.

XML 26 R16.htm IDEA: XBRL DOCUMENT

Retirement Plan	6 Months Ended
Retirement Plan	Jun. 30, 2016
Retirement Plan
Retirement Plan	11. Retirement Plan AxoGen 401(k) Plan The Company adopted the AxoGen 401(k) plan (the “401(k) Plan”) in December 2015 with contributions starting in January 2016. All full-time employees who have attained the age of 18 are eligible to participate in the 401(k) Plan. Eligibility is immediate upon employment and enrollment is available any time during employment. Participating employees may make annual pretax contributions to their accounts up to a maximum amount as limited by law. The 401(k) Plan requires the Company to make matching contributions of 100% on the first 3% of the employee’s annual salary and 50% of the next 2% of the employee’s annual salary as long as the employee participates in the 401(k) Plan and contributes at least 5% of the annual salary. Both employee contributions and Company contributions vest immediately. Employer contributions to this plan for the three and six months ending June 30, 2016, were $92,145 and $171,401, respectively.

XML 27 R17.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Policies)

6 Months Ended

Jun. 30, 2016

Summary of Significant Accounting Policies

Revenue Recognition

Cash and Cash Equivalents and Concentration

Accounts Receivable and Concentration of Credit Risk

Inventories


	June 30,		December 31,
	2016		2015

Finished goods	$	3,243,883	$	2,732,823
Work in process		187,177		237,108
Raw materials		1,355,262		964,029
	$	4,786,322	$	3,933,960

Inventories were net of reserve of approximately $820,000 and $711,000 at June 30, 2016 and December 31, 2015, respectively.

Income Taxes

Fair Value of Financial Instruments

Share-Based Compensation


Six months ended June 30,	2016		2015

Expected term (in years)	4		4
Expected volatility	61.85	%	76.24	%
Risk free rate	1.23	%	1.21	%
Expected dividends	—	%	—	%

Use of Estimates

Recent Accounting Pronouncements

XML 28 R18.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2016

Summary of Significant Accounting Policies

Schedule of inventories


	June 30,		December 31,
	2016		2015

Finished goods	$	3,243,883	$	2,732,823
Work in process		187,177		237,108
Raw materials		1,355,262		964,029
	$	4,786,322	$	3,933,960

Schedule of weighted-average assumptions for options granted


Six months ended June 30,	2016		2015

Expected term (in years)	4		4
Expected volatility	61.85	%	76.24	%
Risk free rate	1.23	%	1.21	%
Expected dividends	—	%	—	%

XML 29 R19.htm IDEA: XBRL DOCUMENT

Property and Equipment (Tables)

6 Months Ended

Jun. 30, 2016

Property and Equipment

Schedule of Property and equipment


	June 30,		December 31,
	2016		2015

Furniture and equipment	$	1,119,698	$	1,186,815
Leasehold improvements		490,214		346,642
Processing equipment		1,756,214		1,375,759
Less: accumulated depreciation and amortization		(2,105,936)		(1,938,346)

Property and equipment	$	1,260,190	$	970,870

XML 30 R20.htm IDEA: XBRL DOCUMENT

Intangible Assets (Tables)

6 Months Ended

Jun. 30, 2016

Intangible Assets

Schedule of intangible assets


	June 30,		December 31,
	2016		2015

License agreements	$	907,545	$	897,594
Patents		267,387		179,997
Less: accumulated amortization		(431,542)		(399,509)
Intangible assets, net	$	743,390	$	678,082

XML 31 R21.htm IDEA: XBRL DOCUMENT

Accounts Payable and Accrued Expenses (Tables)

6 Months Ended

Jun. 30, 2016

Accounts Payable and Accrued Expenses

Schedule of accounts payable and accrued expenses


	June 30,		December 31,
	2016		2015
Accounts payable	$	1,863,349	$	2,090,874
Miscellaneous accruals		358,221		15,183
Accrued compensation		1,672,264		1,589,070
Accounts Payable and Accrued Expenses	$	3,893,834	$	3,695,127

XML 32 R22.htm IDEA: XBRL DOCUMENT

Term Loan Agreement (Tables)

6 Months Ended

Jun. 30, 2016

Term Loan Agreement

Schedule of Term Loan Agreement


	June 30,		December 31,
	2016		2015
Term Loan and Revenue Interest Agreement with Three Peaks Capital S.a.r.l. for a total term loan amount of $25,000,000 which has a six year term and requires interest only payments and a final principal payment due at the end of the term. Interest is payable quarterly at 9.00% per annum plus the greater of LIBOR or 1.0% which as of June 30, 2016 and December 31, 2015 resulted in a 10% rate. The Revenue Interest Agreement is for a period of ten years. Royalty payments are based on a royalty rate of 3.75% of revenues up to a maximum of $30 million in revenues in any 12 month period.	$	24,952,201	$	24,701,693
Long-term portion	$	24,952,201	$	24,701,693

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6479336&loc=d3e64711-112823

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=34725769&loc=d3e28878-108400

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21538-112644

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28541-108399

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28551-108399

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21521-112644

+ Details

XML 33 R23.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Accounts Receivable and Concentration of Credit Risk (Details) - USD ($)	6 Months Ended
	Jun. 30, 2016	Dec. 31, 2015
Accounts Receivable and Concentration of Credit Risk
Reserve for accounts deemed uncollectible (as a percent)	100.00%
Allowance for doubtful accounts reserve balance	$ 241,000	$ 192,000
Minimum
Accounts Receivable and Concentration of Credit Risk
Age of doubtful accounts	60 days
Age 61 to 90 Days
Accounts Receivable and Concentration of Credit Risk
Reserve for doubtful accounts (as a percent)	5.00%
Age 61 to 90 Days \| Minimum
Accounts Receivable and Concentration of Credit Risk
Age of doubtful accounts	61 days
Age 61 to 90 Days \| Maximum
Accounts Receivable and Concentration of Credit Risk
Age of doubtful accounts	90 days
Age Over 90 Days
Accounts Receivable and Concentration of Credit Risk
Reserve for doubtful accounts (as a percent)	20.00%
Age Over 90 Days \| Minimum
Accounts Receivable and Concentration of Credit Risk
Age of doubtful accounts	90 days

XML 34 R24.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Inventories (Details) - USD ($)	Jun. 30, 2016	Dec. 31, 2015
Summary of Significant Accounting Policies
Finished goods	$ 3,243,883	$ 2,732,823
Work in process	187,177	237,108
Raw materials	1,355,262	964,029
Inventory, Net	4,786,322	3,933,960
Inventory valuation reserves	$ 820,000	$ 711,000

XML 35 R25.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Stock-Based Compensation (Details)	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Summary of Significant Accounting Policies
Expected term	4 years	4 years
Expected volatility (as a percent)	61.85%	76.24%
Risk free rate (as a percent)	1.23%	1.21%

XML 36 R26.htm IDEA: XBRL DOCUMENT

Property and Equipment (Details) - USD ($)	Jun. 30, 2016	Dec. 31, 2015
Property and equipment
Less: accumulated depreciation and amortization	$ (2,105,936)	$ (1,938,346)
Property and equipment	1,260,190	970,870
Furniture and Office Equipment
Property and equipment
Property and equipment, Gross	1,119,698	1,186,815
Leasehold Improvements
Property and equipment
Property and equipment, Gross	490,214	346,642
Processing equipment
Property and equipment
Property and equipment, Gross	$ 1,756,214	$ 1,375,759

XML 37 R27.htm IDEA: XBRL DOCUMENT

Intangible Assets - Components of Intangible Assets (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015
Intangible assets consist of:
Less: accumulated amortization	$ (431,542)		$ (431,542)		$ (399,509)
Intangible assets, net	743,390		743,390		678,082
Amortization of Intangible Assets	16,000	$ 11,000	32,033	$ 22,710
Licensing Agreements
Intangible assets consist of:
Finite-lived intangible assets, gross	907,545		$ 907,545		897,594
Licensing Agreements \| Minimum
Intangible assets consist of:
Amortization period of intangible assets			17 years
Licensing Agreements \| Maximum
Intangible assets consist of:
Amortization period of intangible assets			20 years
Patents
Intangible assets consist of:
Finite-lived intangible assets, gross	$ 267,387		$ 267,387		$ 179,997
Amortization period of intangible assets			3 years
Non-amortizable pending costs			$ 267,387

XML 38 R28.htm IDEA: XBRL DOCUMENT

Intangible Assets - Future Amortization Expense (Details)	Jun. 30, 2016 USD ($)
Future amortization of license and patent agreements
Remainder of 2016	$ 32,000
2017	64,000
2018	64,000
2019	64,000
2020	64,000
2021	64,000
2022	64,000
2023	$ 60,000

XML 39 R29.htm IDEA: XBRL DOCUMENT

Intangible Assets - License Agreements (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Sales and Marketing Expense
Intangible assets
Royalty fees included in sales and marketing expense	$ 217,000	$ 121,000	$ 370,000	$ 217,000
Licensing Agreements
Intangible assets
License agreements extended period			60 days
Minimum royalty of agreements			$ 12,500
Milestone fee upon receiving a Phase II Small Business Innovation Research			15,000
Milestone fee upon FDA approval			2,000
Milestone fee upon first commercial use of certain licensed technology			25,000
Milestone fee upon first use to manufacture products that utilize certain technology not currently incorporated into AxoGen products			$ 10,000
Licensing Agreements \| Minimum
Intangible assets
Royalty fees range under the license agreements			1.00%
Licensing Agreements \| Maximum
Intangible assets
Royalty fees range under the license agreements			3.00%
Royalty stack cap for royalties paid to more than one licensor for sales of the same product			3.75%

XML 40 R30.htm IDEA: XBRL DOCUMENT

Accounts Payable and Accrued Expenses (Details) - USD ($)	Jun. 30, 2016	Dec. 31, 2015
Accounts Payable and Accrued Liabilities
Accounts payable	$ 1,863,349	$ 2,090,874
Miscellaneous accruals	358,221	15,183
Accrued compensation	1,672,264	1,589,070
Accounts Payable and Accrued Expenses	$ 3,893,834	$ 3,695,127

XML 41 R31.htm IDEA: XBRL DOCUMENT

Term Loan Agreement - Long-term Portion (Details) - USD ($)	Jun. 30, 2016	Dec. 31, 2015
Note Payable
Total Debt	$ 24,952,201	$ 24,701,693
Long-term Debt. \| ASU 2015-03
Note Payable
Deferred financing costs	782,000	846,000
Other Assets \| ASU 2015-03
Note Payable
Deferred financing costs		(846,000)
Term Loan And Revenue Interest Purchase Agreement
Note Payable
Long-term Notes Payable	24,952,201	24,701,693
Three Peaks \| Term Loan
Note Payable
Long-term Notes Payable	$ 24,952,201	$ 24,701,693

XML 42 R32.htm IDEA: XBRL DOCUMENT

Note Payable and Term Loan Agreement - Term Loan Agreement and Revenue Interest Agreement (Details) - USD ($)		3 Months Ended
	Nov. 12, 2014	Sep. 30, 2016	Jun. 30, 2016	Dec. 31, 2015	Nov. 13, 2014
Debt Instrument [Line Items]
Shares of common stock sold			30,128,099	29,984,591
Value of common stock sold			$ 301,281	$ 299,846
Three Peaks
Debt Instrument [Line Items]
Shares of common stock sold	1,375,969
Value of common stock sold	$ 3,550,000
Public offering price (in dollars per share)	$ 2.58
Term Loan \| Three Peaks
Debt Instrument [Line Items]
Term	6 years
Interest payable	9.00%
Face amount	$ 25,000,000
Basis spread on fixed rate, option 1	LIBOR
Basis spread on fixed rate, option 2	1.00%
Effective interest rate (as a percent)			10.00%	10.00%	10.00%
Upon certain events, the percentage of outstanding principal amount of the Term Loan the Company has the option to prepay and the lender has a right to demand payment for on or prior to the first anniversary of the applicable Closing Date	120.00%
Upon certain events, the percentage of outstanding principal amount of the Term Loan the Company has the option to prepay and the lender has a right to demand payment for after the first anniversary but before the second anniversary of the applicable Closing Date	135.00%
Upon certain events, the percentage of outstanding principal amount of the Term Loan the Company has the option to prepay and the lender has a right to demand payment for after the second anniversary but before the third anniversary of the applicable Closing Date	150.00%
Upon certain events, the internal rate of return of the outstanding principal amount of the Term Loan the Company has the option to prepay and the lender has a right to demand after the third anniversary of the applicable Closing Date	16.25%
Upon certain events, the additional percentage of the originally advanced Term Loan amount owed	3.00%
Term Loan \| Three Peaks \| Forecast
Debt Instrument [Line Items]
Optional future additional borrowing		$ 7,000,000
Revenue Interest Purchase Agreement \| Three Peaks
Debt Instrument [Line Items]
Term	10 years
Royalty percentage on net revenue	3.75%
Revenue Interest Purchase Agreement \| Three Peaks \| Maximum
Debt Instrument [Line Items]
Royalty percentage on net revenue	4.80%
Royalty revenue per year	$ 30,000,000

XML 43 R33.htm IDEA: XBRL DOCUMENT

Stock Options (Details) - USD ($)	3 Months Ended		6 Months Ended		8 Months Ended
Stock Options (Details) - USD ($)	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Mar. 31, 2016
Stock-based compensation			$ 752,789	$ 696,625
Stock Options
Stock options granted (in shares)			505,750
Stock-based compensation	$ 569,834	$ 328,376	$ 696,625	$ 752,789
Total future stock compensation expense related to nonvested awards	2,959,000		$ 2,959,000
Stock Options, Contingency Condition Approved
Stock options granted (in shares)					739,000
Stock-based compensation	$ 272,240

XML 44 R34.htm IDEA: XBRL DOCUMENT

Public Offering of Common Stock (Details) - USD ($)	Aug. 26, 2015	Feb. 13, 2015	Feb. 05, 2015	Jun. 30, 2016	Dec. 31, 2015
Shares of common stock sold				30,128,099	29,984,591
Par value of common stock				$ 0.01	$ 0.01
Offering
Shares of common stock sold			4,728,000
Public offering price (in dollars per share)			$ 2.75
Underwriting Agreement
Shares of common stock sold			709,200
Number of days to underwriter to sell additional common shares			30 days
Offering inclusive of over-allotment option
Shares of common stock sold		5,437,200
Public offering price (in dollars per share)		$ 2.75
Gross proceeds from issuance of common stock		$ 15,000,000
Underwriting discounts, commissions and other estimated offering expenses		$ 1,400,000
Securities Purchase Agreement
Offering expenses	$ 300,000
ESSEX \| Securities Purchase Agreement
Shares of common stock sold	4,861,111
Public offering price (in dollars per share)	$ 3.60
Gross proceeds from issuance of common stock	$ 17,500,000

XML 45 R35.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Details)			6 Months Ended
Commitments and Contingencies (Details)	Mar. 16, 2016 ft²	Aug. 06, 2015	Jun. 30, 2016 USD ($)
SNH
Commitments and Contingencies
Additional leased office space in square feet \| ft²	7,050
Leased office space in square feet \| ft²	11,761
Additional term of agreement, if extended	3 years
Additional extension term after expiration date	5 years
Estimated future minimum rental payments on the leases
Year 1			$ 123,000
Year 2			127,000
Year 3			131,000
Year 4			135,000
Year 5			139,000
License and Services Agreement
Commitments and Contingencies
Term of agreement		5 years
Number of anniversary after which the agreement could be terminated		2 years
Notice period for termination of contract		18 months
Estimated future minimum rental payments on the leases
License fee			$ 416,000

XML 46 R36.htm IDEA: XBRL DOCUMENT

Retirement Plan (Details)	3 Months Ended	6 Months Ended
Retirement Plan (Details)	Jun. 30, 2016 USD ($)	Jun. 30, 2016 USD ($) item
AxoGen 401K Plan
Defined Benefit Plan
Age limit for eligibility to participate in the plan \| item		18
Required minimum contribution		5.00%
Employer contributions \| $	$ 92,145	$ 171,401
Axogen 401K Plan, employee's contribution of first 3% of annual salary
Defined Benefit Plan
Matching contributions		100.00%
Employee contribution matched, percent		3.00%
Axogen 401K Plan, employee's contribution of next 2% of annual salary
Defined Benefit Plan
Matching contributions		50.00%
Employee contribution matched, percent		2.00%

EXCEL 47 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 49 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 51 FilingSummary.xml IDEA: XBRL DOCUMENT 3.5.0.2 html 73 174 1 false 30 0 false 6 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.axogeninc.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://www.axogeninc.com/role/StatementCondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 00105 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.axogeninc.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://www.axogeninc.com/role/StatementCondensedConsolidatedStatementsOfOperations CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.axogeninc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 5 false false R6.htm 10101 - Disclosure - Basis of Presentation Sheet http://www.axogeninc.com/role/DisclosureBasisOfPresentation Basis of Presentation Notes 6 false false R7.htm 10201 - Disclosure - Organization and Business Sheet http://www.axogeninc.com/role/DisclosureOrganizationAndBusiness Organization and Business Notes 7 false false R8.htm 10301 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 10401 - Disclosure - Property and Equipment Sheet http://www.axogeninc.com/role/DisclosurePropertyAndEquipment Property and Equipment Notes 9 false false R10.htm 10501 - Disclosure - Intangible Assets Sheet http://www.axogeninc.com/role/DisclosureIntangibleAssets Intangible Assets Notes 10 false false R11.htm 10601 - Disclosure - Accounts Payable and Accrued Expenses Sheet http://www.axogeninc.com/role/DisclosureAccountsPayableAndAccruedExpenses Accounts Payable and Accrued Expenses Notes 11 false false R12.htm 10701 - Disclosure - Term Loan Agreement Sheet http://www.axogeninc.com/role/DisclosureTermLoanAgreement Term Loan Agreement Notes 12 false false R13.htm 10801 - Disclosure - Stock Options Sheet http://www.axogeninc.com/role/DisclosureStockOptions Stock Options Notes 13 false false R14.htm 10901 - Disclosure - Public Offering of Common Stock Sheet http://www.axogeninc.com/role/DisclosurePublicOfferingOfCommonStock Public Offering of Common Stock Notes 14 false false R15.htm 11001 - Disclosure - Commitments and Contingencies Sheet http://www.axogeninc.com/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 15 false false R16.htm 11101 - Disclosure - Retirement Plan Sheet http://www.axogeninc.com/role/DisclosureRetirementPlan Retirement Plan Notes 16 false false R17.htm 20302 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPolicies 17 false false R18.htm 30303 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPolicies 18 false false R19.htm 30403 - Disclosure - Property and Equipment (Tables) Sheet http://www.axogeninc.com/role/DisclosurePropertyAndEquipmentTables Property and Equipment (Tables) Tables http://www.axogeninc.com/role/DisclosurePropertyAndEquipment 19 false false R20.htm 30503 - Disclosure - Intangible Assets (Tables) Sheet http://www.axogeninc.com/role/DisclosureIntangibleAssetsTables Intangible Assets (Tables) Tables http://www.axogeninc.com/role/DisclosureIntangibleAssets 20 false false R21.htm 30603 - Disclosure - Accounts Payable and Accrued Expenses (Tables) Sheet http://www.axogeninc.com/role/DisclosureAccountsPayableAndAccruedExpensesTables Accounts Payable and Accrued Expenses (Tables) Tables http://www.axogeninc.com/role/DisclosureAccountsPayableAndAccruedExpenses 21 false false R22.htm 30703 - Disclosure - Term Loan Agreement (Tables) Sheet http://www.axogeninc.com/role/DisclosureTermLoanAgreementTables Term Loan Agreement (Tables) Tables http://www.axogeninc.com/role/DisclosureTermLoanAgreement 22 false false R23.htm 40301 - Disclosure - Summary of Significant Accounting Policies - Accounts Receivable and Concentration of Credit Risk (Details) Sheet http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAccountsReceivableAndConcentrationOfCreditRiskDetails Summary of Significant Accounting Policies - Accounts Receivable and Concentration of Credit Risk (Details) Details 23 false false R24.htm 40302 - Disclosure - Summary of Significant Accounting Policies - Inventories (Details) Sheet http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesInventoriesDetails Summary of Significant Accounting Policies - Inventories (Details) Details 24 false false R25.htm 40303 - Disclosure - Summary of Significant Accounting Policies - Stock-Based Compensation (Details) Sheet http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails Summary of Significant Accounting Policies - Stock-Based Compensation (Details) Details 25 false false R26.htm 40401 - Disclosure - Property and Equipment (Details) Sheet http://www.axogeninc.com/role/DisclosurePropertyAndEquipmentDetails Property and Equipment (Details) Details http://www.axogeninc.com/role/DisclosurePropertyAndEquipmentTables 26 false false R27.htm 40501 - Disclosure - Intangible Assets - Components of Intangible Assets (Details) Sheet http://www.axogeninc.com/role/DisclosureIntangibleAssetsComponentsOfIntangibleAssetsDetails Intangible Assets - Components of Intangible Assets (Details) Details 27 false false R28.htm 40502 - Disclosure - Intangible Assets - Future Amortization Expense (Details) Sheet http://www.axogeninc.com/role/DisclosureIntangibleAssetsFutureAmortizationExpenseDetails Intangible Assets - Future Amortization Expense (Details) Details 28 false false R29.htm 40503 - Disclosure - Intangible Assets - License Agreements (Details) Sheet http://www.axogeninc.com/role/DisclosureIntangibleAssetsLicenseAgreementsDetails Intangible Assets - License Agreements (Details) Details 29 false false R30.htm 40601 - Disclosure - Accounts Payable and Accrued Expenses (Details) Sheet http://www.axogeninc.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails Accounts Payable and Accrued Expenses (Details) Details http://www.axogeninc.com/role/DisclosureAccountsPayableAndAccruedExpensesTables 30 false false R31.htm 40701 - Disclosure - Term Loan Agreement - Long-term Portion (Details) Sheet http://www.axogeninc.com/role/DisclosureTermLoanAgreementLongTermPortionDetails Term Loan Agreement - Long-term Portion (Details) Details 31 false false R32.htm 40702 - Disclosure - Note Payable and Term Loan Agreement - Term Loan Agreement and Revenue Interest Agreement (Details) Sheet http://www.axogeninc.com/role/DisclosureNotePayableAndTermLoanAgreementTermLoanAgreementAndRevenueInterestAgreementDetails Note Payable and Term Loan Agreement - Term Loan Agreement and Revenue Interest Agreement (Details) Details 32 false false R33.htm 40801 - Disclosure - Stock Options (Details) Sheet http://www.axogeninc.com/role/DisclosureStockOptionsDetails Stock Options (Details) Details http://www.axogeninc.com/role/DisclosureStockOptions 33 false false R34.htm 40901 - Disclosure - Public Offering of Common Stock (Details) Sheet http://www.axogeninc.com/role/DisclosurePublicOfferingOfCommonStockDetails Public Offering of Common Stock (Details) Details http://www.axogeninc.com/role/DisclosurePublicOfferingOfCommonStock 34 false false R35.htm 41001 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.axogeninc.com/role/DisclosureCommitmentsAndContingenciesDetails Commitments and Contingencies (Details) Details http://www.axogeninc.com/role/DisclosureCommitmentsAndContingencies 35 false false R36.htm 41101 - Disclosure - Retirement Plan (Details) Sheet http://www.axogeninc.com/role/DisclosureRetirementPlanDetails Retirement Plan (Details) Details http://www.axogeninc.com/role/DisclosureRetirementPlan 36 false false All Reports Book All Reports axgn-20160630.xml axgn-20160630.xsd axgn-20160630_cal.xml axgn-20160630_def.xml axgn-20160630_lab.xml axgn-20160630_pre.xml true true ZIP 53 0001558370-16-007237-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-16-007237-xbrl.zip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end